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Background: Erythropoiesis-stimulating agents (ESAs) are biological drugs used 
to stimulate the production of red blood cells. ESAs are commonly prescribed for cancer 
patients with chemotherapy-induced anemia and chronic kidney disease (CKD) patients 
with low levels of hemoglobin. Due to the increasing safety concerns, Centers for 
Medicare and Medicaid Services (CMS) issued a Medicare reimbursement policy change 
for ESAs in cancer patients to regulate the utilization of ESAs. For chemotherapy-
induced anemia, when patients had solid tumors, multiple myeloma, lymphoma, or 
lymphocytic leukemia, ESA treatment is reimbursable by CMS only when the 
hemoglobin level is < 10g/dL. 
Objectives: The objectives of this study were to (1) examine the utilization of 
ESAs and blood transfusions in cancer patients with chemotherapy-induced anemia 
before and after the implementation of Medicare reimbursement policy; (2) examine the 
impact of Medicare reimbursement policy change on the risks of myocardial infarction 
(MI), stroke, and venous thromboembolism (VTE) in incident users of ESAs with 
chemotherapy-induced anemia; and (3) examine the impact of Medicare reimbursement 
policy change on anemia-related and total medical costs in incident users of ESAs with 
chemotherapy-induced anemia. 
Methods: This study used the Surveillance, Epidemiology, and End Results 
(SEER)-Medicare linked database. A repeated cross-sectional design was used in Aim 1 
and a retrospective incident user cohort design was used in Aim 2 and 3. The treatment 
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group of the study was composed of Medicare beneficiaries with cancer and the control 
group of the study was composed of Medicare beneficiaries with CKD. In Aim 1, an 
interrupted time series design with a control group was used to examine the impact of 
Medicare reimbursement policy change on the utilization of ESAs and blood 
transfusions. In Aim 2, a logistic regression model was used to examine the impact of 
Medicare reimbursement policy change on the risks of MI, stroke, and VTE associated 
with ESAs. In Aim 3, a difference-in-difference design was used to examine the impact 
of Medicare reimbursement policy change on anemia-related and total medical costs 
associated with ESAs. 
Results: After the implementation of Medicare reimbursement policy, the level in 
the monthly utilization of ESAs was reduced by 2.13% (P < .0001) but the trend in the 
monthly utilization of ESAs remained stable (P = .1366). After the implementation of 
Medicare reimbursement policy, the level in the monthly utilization of blood transfusions 
was increased by 0.10% (P = .0186) but the trend in the monthly utilization of blood 
transfusions remained stable (P = .0524). In the adjusted logistic regression analysis, we 
found that the implementation of Medicare reimbursement policy was not associated with 
the future development of MI (OR: 1.01; 95% CI: 0.74-1.39), stroke (OR: 0.99; 95% CI: 
0.84-1.15), and VTE (OR: 0.93; 95% CI: 0.84-1.03). In the adjusted generalized linear 
regression analysis, we found that the implementation of Medicare reimbursement policy 
was associated with a 11.20% (P = .0113) reduction in anemia-related costs (a 9.83% 
reduction in Medicare payment (P = .0310) and a 18.40% reduction in patient cost-
sharing (P < .0001)), and a 11.96% (P = .0001) reduction in total medical costs (a 11.59% 
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reduction in Medicare payment (P = .0003) and a 13.58% reduction in patient cost-
sharing (P < .0001)). 
Conclusion: Medicare reimbursement policy had a one-time only effect on the 
utilization of ESAs and blood transfusions (a relative 50% reduction in the monthly 
utilization of ESAs and a relative 10% increase in the monthly utilization of blood 
transfusions). Medicare reimbursement policy change had no impact on the risks of MI, 
stroke, and VTE associated with ESAs in cancer patients with chemotherapy-induced 
anemia. Medicare reimbursement policy change had an impact on the anemia-related and 
total medical costs associated with ESAs in cancer patients with chemotherapy-induced 
anemia (a 10% reduction in either anemia-related or total medical costs). 
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1.1 Chemotherapy-Induced Anemia 
Among individuals aged 65 years and older, the number of new cancer cases was 
1.0 million in 2010 and it is expected to increase to 1.6 million in 2030 in the United 
States.1 The most recent available data showed that about 30% to 90% of patients with 
cancer also had anemia.2 Anemia is a prevalent complication of myelosuppressive 
chemotherapy and is associated with reduced quality of life.3 Myelosuppressive 
chemotherapy could impair hematopoiesis in the bone marrow and decrease production 
of erythropoietin in the renal.4 The type of malignancy is associated with the incidence 
and severity of chemotherapy-induced anemia.5 Patients with lung tumors, gynecologic 
tumors, genitourinary tumors, lymphomas, and colorectal tumors have a high incidence 
of chemotherapy-induced anemia.3,4 
Anemia can be treated with transfusion of red blood cells or administration of 
erythropoiesis-stimulating agents (ESAs). Transfusion of red blood cells is a rapid 
approach to increase hemoglobin and hematocrit levels in patients with anemia. The 
safety of blood transfusions (e.g. immunosuppression and transfusion reactions), 
however, is a significant concern.6-11 In addition, transfusion of red blood cells is 
inconvenient and time-consuming to patients. 
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1.2 Erythropoiesis-Stimulating Agents 
ESAs are commonly prescribed for cancer patients with chemotherapy-induced 
anemia or chronic kidney disease (CKD) patients with low levels of hemoglobin. ESAs 
are biological drugs used to stimulate the production of red blood cells. Epoetin alfa and 
darbepoetin alfa are two commercially available ESAs in the U.S. market. Epoetin alfa 
and darbepoetin alfa were first approved by the Food and Drug Administration (FDA) in 
1993 and 2002, respectively, for the treatment of anemia associated with cancer 
chemotherapy. ESAs are injections for intravenous or subcutaneous administration. 
Epoetin alfa is a short-acting ESA and is administered one to three times a week; 
darbepoetin alfa is a long-acting ESA and is administered once every one to three weeks. 
Among Medicare beneficiaries with cancer who received chemotherapy, the 
annual utilization of ESAs increased substantially from 5% to 50% in the past two 
decades.12 In 2004, ESAs were the highest-expenditure drug in the Medicare system.13 
For cancer patients, Medicare expenditures for ESAs increased five-fold from $321 
million in 1999 to $1.51 billion in 2004.14 
ESAs are efficacious in increasing hemoglobin and hematocrit levels and 
reducing or avoiding future requirements of blood transfusions in cancer patients with 
chemotherapy-induced anemia.15-25 However, ESAs are found to be associated with 
increased risks of tumor progression or recurrence, mortality, thrombovascular events, 
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1.3 Safety Concerns 
Emerging findings from clinical trials led to FDA’s arrangements of two 
Oncologic Drug Advisory Committee (ODAC) meetings in 2004 and 2007 to assess the 
safety and efficacy profile of ESAs.40,41 The 2007 ODAC recommended to add more 
restrictions on ESA labels and conduct additional clinical trials to understand more about 
the benefits and risks associated with ESAs. 
Based on clinical information, the FDA issued a black-box warning on March 9, 
2007 about the increased risk of death, myocardial infarction (MI), stroke, venous 
thromboembolism (VTE), thrombosis of vascular access, and tumor progression or 
recurrence associated with epoetin alfa and darbepoetin alfa in patients with cancer or 
CKD.42,43 In the labeling of both epoetin alfa and darbepoetin alfa, the initiation of ESAs 
in patients on cancer chemotherapy is appropriate only if the hemoglobin level is < 10 
g/dL.42,43 The labeling, however, does not specify at which hemoglobin level the ESA 
treatment should be suspended.42,43 
To better use current evidence to guide clinical practice, the American Society of 
Clinical Oncology (ASCO) and the American Society of Hematology (ASH) published 
clinical practice guidelines on the use of epoetin alfa and darbepoetin alfa in adult 
patients with cancer in 2002, 2007, and 2010.44-46 The ASCO/ASH guidelines 
recommended that ESAs should be initiated in cancer patients with chemotherapy-
induced anemia when the hemoglobin level has been decreased to < 10 g/dL. When the 
hemoglobin level is ≥ 10 g/dL but < 12 g/dL, whether ESAs should be initiated cannot be 
definitively determined. The ASCO/ASH guidelines did not require monitoring the 
hemoglobin level in the maintenance administration of ESAs. 
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1.4 Medicare Reimbursement Policy Change 
Due to the increasing safety concerns, Centers for Medicare and Medicaid 
Services (CMS) conducted a National Coverage Analysis (NCA) for ESAs in non-renal 
disease indications on May 14, 2007.47 Prior to the NCA, CMS did not have a national 
policy to regulate ESA use in non-renal disease indications. However, based on the 
results of the NCA, CMS proposed a national policy to regulate ESA use in non-renal 
disease indications. 
After reviewing public comments to the NCA, CMS issued a National Coverage 
Determination (NCD) for ESAs in cancer and related neoplastic conditions on July 30, 
2007.48-52 Specifically, for chemotherapy-induced anemia, when patients had solid 
tumors, multiple myeloma, lymphoma, or lymphocytic leukemia, ESA treatment was 
reasonable and necessary only when the hemoglobin level was < 10g/dL or the 
hematocrit level was < 30%.53 Table 1.1 summarized details of the NCD requirements on 
ESA use in chemotherapy-induced anemia. Except for the requirements in the 
hemoglobin for initiation and starting dose, NCD requirements were generally more rigid 
than recommendations in the FDA labelling and ASCO/ASH guidelines for ESAs. 
After the implementation of the NCD, when ESAs were used to treat 
chemotherapy-induced anemia in patients with solid tumors, multiple myeloma, 
lymphoma, or lymphocytic leukemia, Medicare denied payment of services if the 
hemoglobin level was ≥ 10 g/dL or the hematocrit level was ≥ 30%.53 For patients who 
were not qualified for reasonable and necessary use of ESAs, they could still have access 
to ESA treatment. However, they needed to sign an Advance Beneficiary Notice of 
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Noncoverage (ABN) to be 100% liable for payment of services not covered under 
Medicare.54 
Medicare reimbursement policy change on ESAs was only effective in cancer and 
related neoplastic conditions. ESA use in renal disease indications was not regulated by 
this policy. CMS does not have any NCD to regulate ESA use for CKD. 
The NCD became effective on July 30, 2007. By January 1, 2008, providers have 
been required to use a modifier code attached to the Healthcare Common Procedure 
Coding System (HCPCS) codes indicating the purpose of ESA treatment (EA: 
chemotherapy-induced anemia; EB: radiotherapy-induced anemia; and EC: non-
chemotherapy/radiotherapy induced anemia).53 Based on these modifier codes, Medicare 
denied claims for non-renal ESA services when ESA use was considered unreasonable or 
unnecessary on or after January 1, 2008. The full implementation of the NCD was on 
April 7, 2008. Since then, Medicare contractors have been required to review claims to 
ensure the implementation of the NCD. Medicare retracted payment for claims that were 
considered not meeting the NCD requirements on or after April 7, 2008.53 
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Table 1.1: NCD requirements on the ESA treatment in chemotherapy-induced anemia 
 
 Epoetin alfa Darbepoetin alfa  





Only if hemoglobin is < 10 g/dL (or hematocrit is < 30%)  
Hemoglobin for 
maintenance 
Only if hemoglobin is < 10 g/dL (or hematocrit is < 30%)  
Starting dose 150 U/kg three times per week 
or 40,000 U weekly 
2.25 mcg/kg every week or 500 




Maintain the starting dose if hemoglobin increases ≥ 1 g/dL (or 
hematocrit increases ≥ 3%) four weeks after initiation and 
hemoglobin remains < 10 g/dL (or hematocrit remains < 30%). 
 
Dose reduction Reduce dose by 25% if hemoglobin increases > 1 g/dL (or 
hematocrit increases > 3%) in any two-week period and hemoglobin 
remains < 10 g/dL (or hematocrit remains < 30%). 
 
Dose withhold Withhold dose if hemoglobin is ≥ 10 g/dL (or hematocrit is ≥ 30%).  
Dose reinitiate Reinitiate at a dose 25% below the previous dose when hemoglobin 
remains < 10 g/dL (or hematocrit remains < 30%). 
 
Dose increase Increase dose once by 25% if hemoglobin increases < 1 g/dL (or 
hematocrit increases < 3%) after four weeks and hemoglobin 
remains < 10 g/dL (or hematocrit remains < 30%). 
 
Discontinue Discontinue if hemoglobin increases < 1 g/dL (or hematocrit 




Eight weeks following the final dose of chemotherapy in a 
chemotherapy course. 
 
NCD: National Coverage Determination;   ESAs: erythropoiesis-stimulating agents  
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  CHAPTER 2
CONCEPTUAL FRAMEWORK 
 
Many factors could impact ESA prescribing and/or dispensing practices and 
patients’ health outcomes. Based on the conceptual framework by Lipton et al., these 
factors could be categorized into internal and external factors.55 (Figure 2.1) The Lipton 
conceptual framework has been widely used to examine the impact of different factors on 
drug prescribing and/or dispensing practices and patients’ health outcomes.56-72  
This study used the adapted Lipton conceptual framework to understand factors 
influencing the utilization, risks, and costs associated with ESAs. Patient and prescriber 
factors are two internal factors. Patient factors (e.g. demographics, socio-economics, and 
clinical characteristics) could impact ESA prescribing and/or dispensing practices. For 
example, income is one of patient factors when using ESAs. Compare to those with high 
level of income, patients with low level of income are less likely to use ESAs because 
they could not afford the high costs. Prescriber factors (e.g. employment setting, degree 
type, and previous experience) could impact ESA prescribing and/or dispensing practices. 
Previous experience is one of prescriber factors when prescribing ESAs. Prescribers with 
successful previous experience in treating chemotherapy-induced anemia with ESAs are 
more likely to continue to prescribe ESAs. External factors, system factors (e.g. 
reimbursement, drug policies, and practice organization), could also impact ESA 
prescribing and/or dispensing practices. For example, Medicare reimbursement policy 
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change on ESAs is one of system factors. Due to the policy change, ESA prescribing 
and/or dispensing practices will be influenced because unreasonable and unnecessary 
ESA use in cancer patients with chemotherapy-induced anemia will not be reimbursed by 
CMS. The change in ESA prescribing and/or dispensing practices could impact patients’ 
health outcomes (e.g. ESA utilization, adverse events, and medical costs). For example, 
when unsafe ESA prescribing is reduced, the utilization, adverse events, and medical 
costs associated with ESAs may also be reduced. 
The policy evaluated in this study was Medicare reimbursement policy change for 
ESAs in cancer patients. The adapted Lipton conceptual framework is useful in 
identifying other factors influencing the utilization, risks, and costs associated with ESAs. 
This conceptual framework could guide us in identifying potential confounding factors 
that could influence the association between the policy change and health outcomes. We 
should control them in the study. 
Based on the conceptual framework, Medicare reimbursement policy change (an 
external factor) could impact ESA prescribing and/or dispensing practices. Thus, health 
outcomes (including utilization, risks, and costs) associated with ESAs could change after 
the implementation of Medicare reimbursement policy in cancer patients with 
chemotherapy-induced anemia. To make sure that the change in health outcomes was due 
to Medicare reimbursement policy only, we need to control for potential confounding 
factors (other internal and external factors influencing patients’ health outcomes) in the 
study. Internal factors considered in the study include demographics, socio-economics, 
clinical characteristics, tumor characteristics, and treatment characteristics. External 
factors such as guideline revisions and black box warnings should also be considered.  
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For instance, the FDA’s black box warning on ESAs (an external factor) will be 
controlled in the study by incorporating a control group, because it is the first time for the 
FDA to add a black box warning on the labels of ESAs.42,43 On the other hand, 
recommendations in the 2007 ASCO/ASH guidelines (an external factor) are not greatly 
different from recommendations in the 2002 ASCO/ASH guidelines with respect to ESA 





Figure 2.1: Impact of different factors on ESA prescribing/dispensing practices and 
health outcomes                                                                                                                                   








 Drug policies 
 Practice organization 
 … 
Prescriber factors 
 Employment setting 
 Degree type 






 ESA utilization 
 Adverse events 
 Medical costs 
 … 
Internal factors External factors 
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  CHAPTER 3
RESEARCH QUESTIONS 
 
3.1 Aim 1: Utilization 
Aim 1.1: To examine the utilization of ESAs in cancer patients with 
chemotherapy-induced anemia before and after the implementation of Medicare 
reimbursement policy. Before the policy change, Medicare had no national restrictions 
on ESA use; after the policy change, however, Medicare restricted ESA use in cancer at 
the national level. We, therefore, hypothesized a reduction in ESA use following the 
policy change. 
Hypothesis 1.1: In cancer patients with chemotherapy-induced anemia, the 
utilization of ESAs was reduced after Medicare reimbursement policy change. 
Aim 1.2: To examine the utilization of blood transfusions in cancer patients 
with chemotherapy-induced anemia before and after the implementation of 
Medicare reimbursement policy. One of the important clinical benefits of ESA use is to 
reduce future needs of blood transfusions. When ESA use decreases, needs of blood 
transfusions could increase. However, the impact of the policy change on the potential 
increase in blood transfusions was indirect and unintended. We, therefore, hypothesized 
an increase in blood transfusions following the policy change. 
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Hypothesis 1.2: In cancer patients with chemotherapy-induced anemia, the 
utilization of blood transfusions was increased after Medicare reimbursement policy 
change. 
 
3.2 Aim 2: Risks 
Aim 2.1: To examine the impact of Medicare reimbursement policy change 
on the risks of cardiovascular events in incident users of ESAs with chemotherapy-
induced anemia. The purpose of the policy change was to prevent potential harms 
associated with ESAs in Medicare beneficiaries with chemotherapy-induced anemia. MI 
and stroke are two of adverse cardiovascular events listed in the black box warning for 
ESAs. We hypothesized a decrease in the risks of MI and stroke following the policy 
change. 
Hypothesis 2.1: In incident users of ESAs with chemotherapy-induced anemia, 
compared to patients who initiated ESAs before Medicare reimbursement policy change, 
those who initiated ESAs after the policy change were less likely to develop MI and 
stroke. 
Aim 2.2: To examine the impact of Medicare reimbursement policy change 
on the risks of thrombovascular events in incident users of ESAs with 
chemotherapy-induced anemia. VTE is an adverse thrombovascular event listed in the 
black box warning for ESAs. We hypothesized a decrease in the risks of VTE following 
the policy change. 
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Hypothesis 2.2: In incident users of ESAs with chemotherapy-induced anemia, 
compared to patients who initiated ESAs before Medicare reimbursement policy change, 
those who initiated ESAs after the policy change were less likely to develop VTE. 
 
3.3 Aim 3: Costs 
Aim 3.1: To examine the impact of Medicare reimbursement policy change 
on anemia-related costs in incident users of ESAs with chemotherapy-induced 
anemia. Anemia-related costs include costs of ESAs, blood transfusions, and anemia 
treatments. After the policy change, the utilization of ESAs might decrease, the 
utilization of blood transfusions might increase, and the utilization of anemia treatments 
might remain stable. Hence, costs of ESAs might decrease, costs of blood transfusions 
might increase, and costs of anemia treatments might remain stable after the policy 
change. Because costs of ESAs are generally higher than costs of blood transfusions, we 
hypothesized a decrease in anemia-related costs following the policy change. 
Hypothesis 3.1: In incident users of ESAs with chemotherapy-induced anemia, 
anemia-related costs were lower after Medicare reimbursement policy change compared 
to anemia-related costs before the policy change. 
Aim 3.2: To examine the impact of Medicare reimbursement policy change 
on total medical costs in incident users of ESAs with chemotherapy-induced anemia. 
In addition to anemia-related costs, total medical costs (e.g. inpatient costs, outpatient 
costs, and emergency room costs) are another important factor to consider from CMS’s 
perspective. After the policy change, adverse events (e.g. tumor progression or 
recurrence, mortality, thrombovascular events, and cardiovascular events) associated with 
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ESAs might decrease. We hypothesized a decrease in total medical costs following the 
policy change. 
Hypothesis 3.2: In incident users of ESAs with chemotherapy-induced anemia, 
total medical costs were lower after Medicare reimbursement policy change compared to 
total medical costs before the policy change. 
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  CHAPTER 4
LITERATURE REVIEW 
 
4.1 Literature Review on the Utilization 
To date, four studies have examined the change in the utilization of ESAs in 
cancer patients before and after the implementation of Medicare reimbursement policy.73-
76 Hess et al. used electronic medical records from seven practices, including 39 sites of 
care in seven states, and found that the utilization of ESAs significantly decreased from 
41% between June 2006 and March 2007 to 30% between June 2007 and March 2008 (a 
26% reduction, p < .001). Specifically, the utilization of ESAs significantly decreased by 
29% (p < .001) and 24% (p < .001) among patients aged 65 years or older and younger 
than 65 years, respectively.73 Through analyzing medical records at 49 community 
oncology clinics, Henry et al. found that the utilization of ESAs significantly decreased 
from 88% between January 2000 and July 2007 to 56% between August 2007 and 
January 2009 (a 36% reduction, p < .0001).74 Arneson et al. used Medicare 5% sample 
data and focused on patients 66 years or older who had lung cancer, breast cancer, 
colorectal cancer, or lymphomas. Overall, the utilization of ESAs significantly decreased 
from 35% between September and November 2006 to 15% between September and 
November 2007 (a 57% reduction, p < .0001). Specifically, the utilization of ESAs 
significantly decreased by 51%, 55%, 69%, and 57% in patients with lung cancer, breast 
cancer, colorectal cancer, and lymphomas, respectively.75 Hershman et al. used 
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Surveillance, Epidemiology, and End Results (SEER)-Medicare data and focused on 
patients 65 years or older. Annual utilization of ESAs increased from 12% in 2000 to 
16% in 2006 and then decreased to 8% in 2008 (a 51% reduction).76 
Table 4.1 summarized some characteristics of four studies examining the impact 
of Medicare reimbursement policy change on the utilization of ESAs. Hess et al. and 
Henry et al. used medical records and found that the utilization of ESAs had a 29% to 
36% reduction after the policy change.73,74 Using local medical records might not be able 
to measure the impact of the policy change on the utilization of ESAs at the national 
level. Arneson et al. and Hershman et al. used Medicare claims data and found that the 
utilization of ESAs had a 51% to 57% reduction after the policy change.75,76 Using 
Medicare claims data could provide national estimates on the impact of the policy change 
on the utilization of ESAs. Medicare reimbursement policy change was released on July 
30, 2007 and then fully implemented on April 7, 2008. The post-policy periods defined in 
four studies all included the policy implementation period.73-76 Including part of the 
policy implementation period in the post-policy period could bias the estimate on the 
impact of the policy change on the utilization of ESAs. 
In summary, previous studies found a 26% to 57% reduction in the utilization of 
ESAs after the implementation of Medicare reimbursement policy during different time 
periods or in different settings. These studies, however, lack control groups which cast 
doubt on the validity of the generated results. Furthermore, no studies have examined the 
utilization of ESAs during the complete pre- and post-policy periods. Therefore, the long-




Six studies have examined the change in the utilization of blood transfusions in 
cancer patients before and after the implementation of Medicare reimbursement policy.73-
78 Vekeman et al. conducted a simulation study and estimated that if the utilization of 
ESAs reduces by 25%, 50%, and 75%, requirements of blood supply will increase by 9%, 
17%, and 26% in 2008, respectively.77 Hess et al. found that the utilization of blood 
transfusions significantly increased from 8% between June 2006 and March 2007 to 9% 
between June 2007 and March 2008 (a 17% increase, p = .015). The increase in the 
utilization of blood transfusions was mainly driven by patients aged 65 years and older (a 
31% increase, p = .007). Among patients aged less than 65 years, the utilization of blood 
transfusions did not change significantly (a 8% increase, p = .358).73 Yu et al. reviewed 
medical records at the University of Illinois Medical Center and found that significantly 
more blood transfusions were given to patients between July 2006 and June 2007 than 
between July 2007 and June 2008 (18 in 55 versus 52 in 55, p = .004).78 A study by 
Henry et al. found that compared to the period between January 2000 and July 2007, the 
period between August 2007 and January 2009 had more blood transfusions (odds ratio 
[OR]: 1.41; 95% confidence interval [CI]: 1.05-1.89) and required more blood supply 
(OR: 1.53; 95% CI: 1.15-2.04).74 Arneson et al. found that compared to the period 
between September and November 2006, the utilization of blood transfusions did not 
change significantly in the period between September and November 2007 overall and in 
patients with different types of cancer.75 Hershman et al. found that from 2000 to 2008, 




Table 4.2 summarized some characteristics of six studies examining the impact of 
Medicare reimbursement policy change on the utilization of blood transfusions. Vekeman 
et al. used data from published literature and conducted modeling simulation to predict 
the increase in blood supply based on the reduction in ESAs.77 Hess et al., Yu et al., and 
Henry et al. used medical records and found that the utilization of blood transfusions had 
a small increase after the policy change.73,74,78 Using local medical records might not be 
able to measure the impact of the policy change on the utilization of blood transfusions at 
the national level. Arneson et al. and Hershman et al. used Medicare claims data and 
found that the utilization of blood transfusions did not change after the policy change.75,76 
Using Medicare claims data could provide national estimates on the impact of the policy 
change on the utilization of blood transfusions. Medicare reimbursement policy change 
was released on July 30, 2007 and then fully implemented on April 7, 2008. The post-
policy periods defined in six studies all included the policy implementation period.73-78 
Including part of the policy implementation period in the post-policy period could bias 
the estimate on the impact of the policy change on the utilization of blood transfusions. 
In summary, previous studies are controversial regarding the change in the 
utilization of blood transfusions after the implementation of Medicare reimbursement 
policy during different time periods or in different settings. These studies, however, lack 
control groups which cast doubt on the validity of the generated results. Furthermore, no 
studies have examined the utilization of blood transfusions during the complete pre- and 
post-policy periods. Therefore, the long-term effect of Medicare reimbursement policy 




4.2 Literature Review on the Risks 
To date, no studies have examined whether the risks associated with ESAs have 
been reduced after the implementation of Medicare reimbursement policy. This 
information is of great importance to CMS, as reducing potential risks associated with 
ESAs is the goal of the policy change. Therefore, empirical evidence is greatly needed to 
examine the effectiveness of the policy change in addressing safety concerns of ESAs. 
 
4.3 Literature Review on the Costs 
No studies have examined the impact of Medicare reimbursement policy change 
on medical costs associated with ESAs. In the U.S., CMS is the largest payer in 
healthcare. ESAs were the highest-expenditure drug in the Medicare system before the 
policy change. The economic consequence of the policy change should be of great 
interest to CMS. However, empirical evidence is currently lacking to evaluate the 
economic consequence of the policy change among users of ESAs. 
 
4.4 Literature Gap 
This study, therefore, filled three gaps in the literature by: (1) examining the 
utilization of ESAs and blood transfusions by containing a control group and including 
the complete pre- and post-policy periods; (2) evaluating the impact of Medicare 
reimbursement policy change on the risks associated with ESAs to determine if the goal 
of the policy change has been achieved; and (3) evaluating the impact of Medicare 
reimbursement policy change on the costs associated with ESAs to measure the economic 






Table 4.1: Studies examining the impact of Medicare reimbursement policy change on the utilization of ESAs 
 
Author (Year) Data source Sample size Pre-policy period Post-policy period Outcomes Results 
Hess73 (2010) Medical records 
from 7 practices 
4,784 in the pre-policy 
period and 5,605 in the 
post-policy period 
June 2006 to 
March 2007  
June 2007 to 
March 2008  
Utilization of 
ESAs in the study 
period 
Changed from 41% in the 
pre-policy period to 30% in 
the post-policy period 
Henry74 (2012) Medical records at 
49 community 
oncology clinics 
800 in the pre-policy 
period and 994 in the 
post-policy period 
January 2000 to 
July 2007 
August 2007 to 
January 2009 
Utilization of 
ESAs in the study 
period 
Changed from 88% in the 
pre-policy period to 56% in 





1,897 in the pre-policy 
period and 1,877 in the 
post-policy period 
September 2006 to 
November 2006  
September 2007 to 
November 2007  
Utilization of 
ESAs in the study 
period 
Changed from 35% in the 
pre-policy period to 15% in 





Different in different 
years 
2006 2008 Annual utilization 
of ESAs 
Changed from 16% in 2006 
to 8% in 2008  






Table 4.2: Studies examining the impact of Medicare reimbursement policy change on the utilization of blood transfusions 
 
Author (Year) Data source Sample size Pre-policy period Post-policy period Outcomes Results 
Vekeman77 
(2009) 
Simulation Different in different 
assumptions 
2004 2008 Incremental 
requirements of 
blood supply 
If the utilization of ESAs 
reduces by 25%, 50%, and 
75%, requirements of 
blood supply will increase 
by 9%, 17%, and 26% in 
2008, respectively 
Hess73 (2010) Medical records 
from 7 practices 
4,784 in the pre-policy 
period and 5,605 in the 
post-policy period 
June 2006 to 
March 2007  
June 2007 to 
March 2008  
Utilization of 
blood transfusions 
in the study period 
Changed from 8% in the 
pre-policy period to 9% in 
the post-policy period 
Yu78 (2011) Medical records at 
the University of 
Illinois Medical 
Center 
55 in the pre-policy 
period and 55 in the 
post-policy period 
July 2006 to June 
2007  




in the study period 
More blood transfusions 
were given in the post-
policy period (18 in 55 
versus 52 in 55) 
Henry74 (2012) Medical records at 
49 community 
oncology clinics 
800 in the pre-policy 
period and 994 in the 
post-policy period 
January 2000 to 
July 2007 
August 2007 to 
January 2009 
Odds of receiving 
blood transfusions 
Higher odds of receiving 
blood transfusions in the 
post-policy period (OR: 





1,897 in the pre-policy 
period and 1,877 in the 
post-policy period 
September 2006 to 
November 2006  
September 2007 to 
November 2007  
Utilization of 
blood transfusions 
in the study period 






Different in different 
years 
2006 2008 Annual utilization 
of blood 
transfusions 
No change in the post-
policy period 
ESAs: erythropoiesis-stimulating agents;   OR: odds ratio;   CI: confidence interval;   SEER: Surveillance, Epidemiology, and End Results 
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  CHAPTER 5
RESEARCH METHOD 
 
5.1 Data Source 
The SEER program is a large population-based cancer registry which collects 
information on cancer incidence and mortality.79 The National Cancer Institute (NCI) 
developed and maintains the SEER program. Currently, the SEER program includes 
cancer registries across 14 states and covers 28% of the U.S. population. Population-
based cancer registries of the SEER program include Alaska Native Tumor Registry, 
Arizona Indians, Cherokee Nation, Connecticut, Detroit, Georgia Center for Cancer 
Statistics, Greater Bay Area Cancer Registry, Greater California, Hawaii, Iowa, 
Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and 
Utah. The information collected in the SEER program includes demographics, cancer 
type, primary tumor site, tumor morphology, stage at diagnosis, first course of treatment, 
and follow-up for vital status. 
Medicare is a national health insurance program administered by the U.S. federal 
government.80 Medicare provides health insurance for Americans who are 65 years of age 
or older, under 65 years of age but with certain disabilities, or have end-stage renal 
disease (ESRD). Medicare provides hospital insurance (Part A) and medical insurance 
(Part B) to its beneficiaries. Since 2006, Medicare provides prescription drug coverage 
(Part D) to its beneficiaries. Medicare enrollment data include the eligibility and 
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demographic information of Medicare beneficiaries. Medicare claims are submitted by 
healthcare providers for services provided to Medicare beneficiaries. CMS then reviews 
Medicare claims and determines if these services should be reimbursed. The information 
available in Medicare enrollment and claims data includes eligibility, demographics, 
diagnosis, health service utilization, and payments for Medicare beneficiaries.  
The enrollment and claims of Medicare beneficiaries in the SEER program can be 
identified and linked by a collaborative effort of NCI and CMS.81 The SEER-Medicare 
linked data include two cohorts of people: cancer cohort and non-cancer cohort. The 
cancer cohort is defined as Medicare beneficiaries in the SEER program. The non-cancer 
cohort is defined as a random 5% sample of Medicare beneficiaries who do not have 
cancer but reside in the same SEER geographic areas. The non-cancer cohort is usually 
used for comparison purposes. 
This study used the SEER-Medicare linked database. It is an appropriate dataset 
for this study because the linked database contains rich information on demographics, 
cancer incidence and mortality, health service utilization, diagnosis, and payments for 
Medicare beneficiaries with cancer. In addition, it allows us to incorporate a comparison 
group of non-cancer controls. 
 
5.2 Study Design 
This study used different study designs for different outcomes because units of 
analysis were different. When examining utilization, the unit of analysis was the group; 
when examining risks and costs, the unit of analysis was the individual. 
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This study used a repeated cross-sectional design in Aim 1. The repeated cross-
sectional design enabled us to estimate the monthly utilization of ESAs and blood 
transfusions in the treatment and control group. The monthly utilization of ESAs and 
blood transfusions was compared before and after Medicare reimbursement policy 
change. In Aim 1, the period between January 1, 2003 and June 30, 2007 was defined as 
the pre-policy period; the period between July 1, 2007 and April 30, 2008 was defined as 
the policy period; and the period between May 1, 2008 and December 31, 2009 was 
defined as the post-policy period. We selected January 1, 2003 as the starting point 
because darbepoetin alfa was first approved by the FDA in 2002 and fully available on 
the U.S. market starting in 2003 for the treatment of anemia associated with cancer 
chemotherapy. We selected December 31, 2009 as the ending point because ESA Risk 
Evaluation and Mitigation Strategies (REMS), a policy change for ESAs by the FDA, 
came into effect after that.82,83 The selection of the policy period was based on the 
timeline of Medicare reimbursement policy change. The NCD was released on July 30, 
2007 and fully implemented on April 7, 2008. Thus, we selected the period between July 
1, 2007 and April 30, 2008 as the policy period. 
This study used a retrospective incident user cohort design in Aim 2 and 3.84 The 
index date for the incident user of ESAs was the date of the first ESA prescription. The 
cohort design enabled us to estimate the incidence of cardiovascular and thrombovascular 
events in Aim 2. Incident users of ESAs before and after Medicare reimbursement policy 
change were followed up to one year since the index date for a diagnosis of MI, stroke, or 
VTE. Odds ratios of cardiovascular and thrombovascular events between the pre- and 
post-policy periods were estimated. In addition, the cohort design enabled us to estimate 
 
25 
anemia-related and total medical costs since the initiation of ESAs in Aim 3. Costs were 
measured in the treatment and control groups during the one-year follow-up period after 
the index date. Then the cost differences in the treatment and control groups between the 
pre- and post-policy periods were estimated. In Aim 2 and 3, individuals who initiated 
ESAs between May 1, 2005 and December 31, 2006 were considered as incident users in 
the pre-policy period; individuals who initiated ESAs between May 1, 2008 and 
December 31, 2009 were considered as incident users in the post-policy period. We 
selected the post-policy period first based on the timeline of Medicare reimbursement 
policy change and then selected the corresponding pre-policy period. 
 
5.3 Control Group 
Selecting an appropriate control group was essential to the success of this study. 
This study incorporated a CKD control group in Aim 1 and 3. The treatment group was 
composed of Medicare beneficiaries with cancer and the control group was composed of 
Medicare beneficiaries with CKD. We used CKD patients as the control group because 
ESAs can be used in CKD patients with low levels of hemoglobin and Medicare 
reimbursement policy change on ESAs was only applicable to cancer patients. ESA use 
in CKD patients have not been affected by this policy change. Furthermore, FDA’s black 
box warning on ESAs applied to both conditions (cancer and CKD).42,43 Therefore, using 
Medicare beneficiaries with CKD as the control group could eliminate possible threats to 
internal validity due to history (FDA’s black box warning) when evaluating the 




5.4 Study Population 
The study population in Aim 1 was selected based on certain inclusion and 
exclusion criteria in each month. The study population of the treatment group in each 
month was selected from individuals who were aged 65 years or older, were eligible for 
Medicare because of age, had a primary diagnosis of breast cancer, colorectal cancer, 
lung cancer, lymphomas, ovarian cancer, or prostate cancer, and received chemotherapy 
after cancer diagnosis as recorded in the cancer cohort of the SEER-Medicare data. 
Individuals who enrolled in health maintenance organization (HMO) plans, did not have 
coverage of both Medicare Part A and B, were eligible for Medicare because of ESRD, or 
had a diagnosis of CKD were excluded from the treatment group in each month. The 
study population of the control group in each month was selected from individuals who 
were aged 65 years or older and were eligible for Medicare because of ESRD or had a 
diagnosis of CKD as recorded in the non-cancer cohort of the SEER-Medicare data. 
Individuals enrolled in HMO plans, did not have coverage of both Medicare Part A and 
B, or had a diagnosis of cancer were excluded from the control group in each month. 
The study population in Aim 2 was selected from individuals who were aged 66 
years or older, were eligible for Medicare because of age, had a primary diagnosis of 
breast cancer, colorectal cancer, lung cancer, lymphomas, ovarian cancer, or prostate 
cancer, received chemotherapy after cancer diagnosis, initiated ESAs after chemotherapy, 
and initiated ESAs during the study period as recorded in the cancer cohort of the SEER-
Medicare data. Individuals who enrolled in HMO plans, did not have coverage of both 
Medicare Part A and B, were eligible for Medicare because of ESRD, had a diagnosis of 
CKD, or received ESAs one year before the index date were excluded from the study. To 
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identify the study population free of MI, we additionally excluded individuals who had a 
diagnosis of MI one year before the index date. To identify the study population free of 
stroke, we additionally excluded individuals who had a diagnosis of stroke one year 
before the index date. To identify the study population free of VTE, we additionally 
excluded individuals who had a diagnosis of VTE one year before the index date. 
The study population of the treatment group in Aim 3 was selected from 
individuals who were aged 66 years or older, were eligible for Medicare because of age, 
had a primary diagnosis of breast cancer, colorectal cancer, lung cancer, lymphomas, 
ovarian cancer, or prostate cancer, received chemotherapy after cancer diagnosis, 
initiated ESAs after chemotherapy, and initiated ESAs during the study period as 
recorded in the cancer cohort of the SEER-Medicare data. Individuals who enrolled in 
HMO plans, did not have coverage of both Medicare Part A and B, were eligible for 
Medicare because of ESRD, had a diagnosis of CKD, or received ESAs one year before 
the index date were excluded from the treatment group. The study population of the 
control group in Aim 3 was selected from individuals who were aged 66 years or older, 
were eligible for Medicare because of ESRD or had a diagnosis of CKD, initiated ESAs 
after CKD diagnosis, and initiated ESAs during the study period as recorded in the non-
cancer cohort of the SEER-Medicare data. Individuals who enrolled in HMO plans, did 
not have coverage of both Medicare Part A and B, had a diagnosis of cancer, or received 







The utilization of ESAs was measured based on relevant HCPCS/Current 
Procedural Terminology (CPT) and revenue center codes from Medicare claims. The 
utilization of blood transfusions was measured based on relevant International 
Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) and 
HCPCS/CPT codes from Medicare claims. 
To measure cardiovascular and thrombovascular events, incident users of ESAs 
were followed up to one year for an event of MI, stroke, or VTE. The diagnosis of MI, 
stroke, or VTE was measured based on relevant codes in the ICD-9-CM and 
HCPCS/CPT from Medicare claims during the one-year follow-up period. 
Medical costs in the study were measured from CMS’s perspective. To measure 
anemia-related and total medical costs, incident users of ESAs were followed up to one 
year. Anemia-related and total medical costs were measured based on payment 
information from Medicare claims, including Medicare provider, carrier, outpatient, 
home health agency, hospice, and durable medical equipment, during the one-year 
follow-up period. Anemia-related costs included costs of ESAs, blood transfusions, and 
anemia treatments as recorded in Medicare claim. Total medical costs included all costs 
as recorded in Medicare claims. Anemia-related and total medical costs were composed 
of Medicare payment and patient cost-sharing. Consumer price index (CPI) of medical 
care services was used in the study to calculate the inflation rate and adjust medical costs 
occurred in different years to 2010 prices.85 (Table 5.1) 
Variables in the inclusion and exclusion criteria were measured based on the 
SEER registries and Medicare enrollment and claims. Chemotherapy was measured 
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based on relevant ICD-9-CM, HCPCS/CPT and revenue center codes from Medicare 
claims. Patients with breast cancer, colorectal cancer, lung cancer, lymphomas, ovarian 
cancer, or prostate cancer were identified from the SEER registries. Patients with CKD 
were identified from relevant ICD-9-CM codes from Medicare claims. 
The main independent variable of the study was the policy change. Based on the 
conceptual framework, potential confounding factors included demographics, socio-
economics, clinical characteristics, tumor characteristics, and treatment characteristics. 
Specifically, covariates considered in the regression model in Aim 2 were demographics 
(including age, sex, and race), socio-economics (including residence, region, education 
level, and poverty level), clinical characteristics (including Charlson comorbidity index 
(CCI) and vital status), tumor characteristics (including cancer type), and treatment 
characteristics (including surgery and radiation therapy). Covariates considered in the 
regression model in Aim 3 were demographics (including age, sex, and race), socio-
economics (including residence, region, education level, and poverty level), and clinical 
characteristics (including CCI and vital status). 
Covariates were measured based on the SEER registries and Medicare enrollment 
and claims. Specifically, education level was measured based on the percent of persons 
25 years or older with less than 12 years of education in the area of residence. The study 
sample was divided into four quartiles based on education (first quartile: 0% to 10.4%; 
second quartile: 10.4% to 16.5%; third quartile: 16.5% to 26.1%; and fourth quartile: 
26.1% to 100%). Poverty level was measured based on the percent of the population 
below the poverty level in the area of residence. The study sample was divided into four 
quartiles based on poverty (first quartile: 0% to 5.25%; second quartile: 5.25% to 9.1%; 
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third quartile: 9.1% to 15.5%; and fourth quartile: 15.5% to 100%). Because all 
individuals in the treatment group had a diagnosis of cancer and all individuals in the 
control group had a diagnosis of CKD, this study calculated the Deyo adaptation of the 
CCI excluding cancer and CKD.86 
 
5.6 Statistical Analysis 
In Aim 1, the monthly utilization of ESAs was calculated in Formula 5.1; the 
monthly utilization of blood transfusions was calculated in Formula 5.2. Percentages of 
patients received ESAs or blood transfusions in each month were compared before and 
after Medicare reimbursement policy change and plotted in graphs. 
 
𝑀𝑜𝑛𝑡ℎ𝑙𝑦 𝑢𝑡𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐸𝑆𝐴𝑠 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑑 𝐸𝑆𝐴𝑠 𝑖𝑛 𝑡ℎ𝑎𝑡 𝑚𝑜𝑛𝑡ℎ




𝑀𝑜𝑛𝑡ℎ𝑙𝑦 𝑢𝑡𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑏𝑙𝑜𝑜𝑑 𝑡𝑟𝑎𝑛𝑠𝑓𝑢𝑠𝑖𝑜𝑛𝑠
=
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑑 𝑏𝑙𝑜𝑜𝑑 𝑡𝑟𝑎𝑛𝑠𝑓𝑢𝑠𝑖𝑜𝑛𝑠 𝑖𝑛 𝑡ℎ𝑎𝑡 𝑚𝑜𝑛𝑡ℎ




In Aim 1, with aggregate data, an interrupted time series design was used to 
examine the impact of Medicare reimbursement policy change on the utilization of ESAs 
and blood transfusions. A segmented regression analysis in Formula 5.3 was used in the 
interrupted time-series design.87 
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𝑌 = 𝛽0 + 𝛽1 𝑀𝑜𝑛𝑡ℎ + 𝛽2 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 + 𝛽3 𝑀𝑜𝑛𝑡ℎ 𝑎𝑓𝑡𝑒𝑟 𝑝𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒
+ 𝛽4 𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 + 𝛽5 𝑀𝑜𝑛𝑡ℎ×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡
+ 𝛽6 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡
+ 𝛽7 𝑀𝑜𝑛𝑡ℎ 𝑎𝑓𝑡𝑒𝑟 𝑝𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 
(Formula 5.3) 
 𝑌 indicates the monthly utilization; 
 𝑀𝑜𝑛𝑡ℎ is the number of months since the beginning of the pre-policy period 
(January 2003); 
 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 is a dummy variable indicating Medicare reimbursement policy 
change; 
o 0: pre-policy period 
o 1: post-policy period 
 𝑀𝑜𝑛𝑡ℎ 𝑎𝑓𝑡𝑒𝑟 𝑝𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 is 0 if 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 equals to 0; or is the number 
of months since the beginning of the post-policy period (May 2008) if 
𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 equals to 1;  
 𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 is a dummy variable indicating the assignment of patients to 
either the treatment or control group; 
o 0: control group 
o 1: treatment group 
 𝑀𝑜𝑛𝑡ℎ×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 is an interaction term between 𝑀𝑜𝑛𝑡ℎ and 
𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡; 
 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 is an interaction term between 
𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 and 𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡;  
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 𝑀𝑜𝑛𝑡ℎ 𝑎𝑓𝑡𝑒𝑟 𝑝𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 is an interaction term 
between 𝑀𝑜𝑛𝑡ℎ 𝑎𝑓𝑡𝑒𝑟 𝑝𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 and 𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡. 
 
 In Formula 5.3, 𝛽0 estimated the base level in the monthly utilization in the 
beginning of the pre-policy period (January 2003) in the control group; 𝛽1 estimated the 
base trend in the monthly utilization during the pre-policy period in the control group; 𝛽2 
estimated the difference in the level in the monthly utilization between the end of the pre-
policy period (June 2007) and the beginning of the post-policy period (May 2008) in the 
control group; 𝛽3 estimated the difference in the trend in the monthly utilization between 
the pre- and post-policy periods in the control group; 𝛽4 estimated the difference in the 
base level in the monthly utilization in the beginning of the pre-policy period (January 
2003) between the treatment and control groups; 𝛽5 estimated the difference in the base 
trend in the monthly utilization during the pre-policy period between the treatment and 
control groups; 𝛽6 estimated the difference in the difference in the level in the monthly 
utilization between the end of the pre-policy period (June 2007) and the beginning of the 
post-policy period (May 2008) between the treatment and control groups; 𝛽7 estimated 
the difference in the difference in the trend in the monthly utilization between the pre- 
and post-policy periods between the treatment and control groups. Among them, 𝛽6 and 
𝛽7 were two coefficients of interest. They indicated if there were any differences in the 
level and trend in the monthly utilization of ESAs or blood transfusions between the pre- 
and post-policy periods between the treatment and control groups. The monthly 
utilization of ESAs or blood transfusions during the policy period, the period between 
July 1, 2007 and April 30, 2008, were excluded in the segmented regression analysis. 
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In Aim 2 and 3, we conducted a descriptive analysis on characteristics of incident 
users of ESAs between the pre- and post-policy periods. Basic statistical tests (Chi-square 
or Fisher’s exact test) were used to compare baseline characteristics of incident users of 
ESAs before and after Medicare reimbursement policy change. Significant factors 
associated with the policy change were identified. In Aim 3, we also compared the 
average medical costs in incident users of ESAs between the pre- and post-policy periods 
using the independent sample t-test. For all statistical tests in the study, a 5% level of 
significance was used. 
In Aim 2, with individual data, a logistic regression model in Formula 5.4 was 
used to examine the impact of Medicare reimbursement policy change on the risks of MI, 
stroke, and VTE associated with ESAs. 
 
𝑙𝑛(𝑜𝑑𝑑𝑠 𝑡ℎ𝑎𝑡 𝑌 = 1) = 𝛽0 + 𝛽1𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 + 𝛽2𝐷𝑒𝑚𝑜 + 𝛽3𝑆𝑜𝑐𝑖𝑜 + 𝛽4𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 
                          +𝛽5𝑇𝑢𝑚𝑜𝑟 + 𝛽6𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  
(Formula 5.4) 
 𝑌 is a dummy variable indicating the diagnosis of MI, stroke, or VTE; 
o 0: not diseased 
o 1: diseased 
 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 is a dummy variable indicating Medicare reimbursement policy 
change; 
o 0: pre-policy period 
o 1: post-policy period 
 𝐷𝑒𝑚𝑜 includes a series of demographical variables;  
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 𝑆𝑜𝑐𝑖𝑜 includes a series of socio-economic variables;  
 𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 includes a series of variables indicating clinical characteristics;  
 𝑇𝑢𝑚𝑜𝑟 includes a series of variables indicating tumor characteristics;  
 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 includes a series of variables indicating treatment characteristics. 
 
In Formula 5.4, 𝛽1 was the coefficient of interest. The odds ratio comparing the 
odds of having MI, stroke, or VTE in the post-policy period versus the pre-policy period 
among incident users of ESAs were measured as 𝑒𝛽1. 
In Aim 3, with individual data, a difference-in-difference design was used to 
examine the impact of Medicare reimbursement policy change on anemia-related and 
total medical costs associated with ESAs.88 A generalized linear model (GLM) in 
Formula 5.5, with a log link and a gamma distribution, was used in the difference-in-
difference design. 
 
G(𝜇) = 𝛽0 + 𝛽1𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 + 𝛽2𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡
+ 𝛽3𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 + 𝛽4𝐷𝑒𝑚𝑜 + 𝛽5𝑆𝑜𝑐𝑖𝑜
+ 𝛽6𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 
(Formula 5.5) 
 G(𝜇) indicates log-transformed costs;  
 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 is a dummy variable indicating Medicare reimbursement policy 
change; 
o 0: pre-policy period 
o 1: post-policy period 
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 𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 is a dummy variable indicating the assignment of patients to 
either the treatment or control group; 
o 0: control group 
o 1: treatment group 
 𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒×𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡 is an interaction term between 
𝑃𝑜𝑙𝑖𝑐𝑦 𝑐ℎ𝑎𝑛𝑔𝑒 and 𝐺𝑟𝑜𝑢𝑝 𝑎𝑠𝑠𝑖𝑔𝑛𝑚𝑒𝑛𝑡;  
 𝐷𝑒𝑚𝑜 includes a series of demographical variables;  
 𝑆𝑜𝑐𝑖𝑜 includes a series of socio-economic variables;  
 𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 includes a series of variables indicating clinical characteristics. 
 
In Formula 5.5, 𝛽1 estimated the difference in the log-transformed costs between 
the pre- and post-policy periods in the control group; 𝛽2 estimated the difference in the 
log-transformed costs in the pre-policy period between the treatment and control groups; 
𝛽3 estimated the difference in the difference in the log-transformed costs between the 
pre- and post-policy periods between the treatment and control groups. Among them, 𝛽3 
was the coefficient of interest. It indicated if there were any differences in the log-
transformed anemia-related and total medical costs associated with ESAs between the 
pre- and post-policy periods between the treatment and control groups. 





Table 5.1 CPI and inflation rate of medical care services from 2005 to 2010 
 
Year CPI Inflation rate (2010 prices) 
2005 336.70 1.2213 
2006 350.60 1.1729 
2007 369.30 1.1135 
2008 384.94 1.0682 
2009 397.30 1.0350 
2010 411.21 1.0000 




  CHAPTER 6
RESULTS 
 
6.1 Results on the Utilization 
After applying the inclusion and exclusion criteria in Aim 1, we identified the 
study sample of eligible cancer or CKD patients in each month. (Table 6.1 and 6.2) In the 
treatment group, the total number of eligible cancer patients in each month ranged from 
55,719 to 109,646 from January 2003 to December 2009. In the control group, the total 
number of eligible CKD patients in each month ranged from 28,684 to 64,157 from 
January 2003 to December 2009. 
 
6.1.1 Results on the Utilization of ESAs 
Figure 6.1 illustrated the change in the monthly utilization of ESAs before and 
after the implementation of Medicare reimbursement policy. From visual inspection, we 
found that during the pre-policy period, the monthly utilization of ESAs changed from 
5.23% in January 2003 to 3.15% in June 2007 in the treatment group; and the monthly 
utilization of ESAs changed from 5.68% in January 2003 to 4.66% in June 2007 in the 
control group. During the policy period, the monthly utilization of ESAs had a huge drop 
in the treatment group (from 3.21% in July 2007 to 1.24% in April 2008); and the 
monthly utilization of ESAs had a small drop in the control group (from 4.64% in July 
2007 to 4.15% in April 2008). During the post-policy period, the monthly utilization of 
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ESAs changed from 1.23% in May 2008 to 0.79% in December 2009 in the treatment 
group; and the monthly utilization of ESAs changed from 4.11% in May 2008 to 3.57% 
in December 2009 in the control group.  
To quantity the change in the monthly utilization of ESAs before and after the 
implementation of Medicare reimbursement policy, we conducted a segmented regression 
analysis in the interrupted time-series design. Table 6.3 summarized the results on the 
change in the monthly utilization of ESAs before and after the implementation of 
Medicare reimbursement policy. According to the segmented regression analysis, in the 
treatment group, the monthly utilization of ESAs in the end of the pre-policy period (June 
2007) and the beginning of the post-policy period (May 2008) was estimated as 4.15% 
and 1.19%, respectively. The level in the monthly utilization of ESAs was estimated to be 
reduced by 2.96% after the policy change in the treatment group. In the control group, the 
monthly utilization of ESAs in the end of the pre-policy period (June 2007) and the 
beginning of the post-policy period (May 2008) was estimated as 4.93% and 4.10%, 
respectively. The level in the monthly utilization of ESAs was estimated to be reduced by 
0.83% after the policy change in the control group. Thus, when including the control 
group in the interrupted time-series design, the level in the monthly utilization of ESAs 
was reduced statistically significantly by 2.13% (P < .0001) after the policy change. 
According to the segmented regression analysis, in the treatment group, the trend 
in the monthly utilization of ESAs in the pre- and post-policy period was estimated as -
0.03% and -0.02%, respectively. The trend in the monthly utilization of ESAs was 
estimated to be increased by 0.01% after the policy change in the treatment group. In the 
control group, the trend in the monthly utilization of ESAs in the pre- and post-policy 
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period was estimated as -0.01% and -0.02%, respectively. The trend in the monthly 
utilization of ESAs was estimated to be reduced by 0.01% after the policy change in the 
treatment group. Thus, when including the control group in the interrupted time-series 
design, the trend in the monthly utilization of ESAs was increased by 0.02% (P = .1366) 
after the policy change but was not statistically significant. 
In summary, the utilization of ESAs in cancer patients with chemotherapy-
induced anemia was reduced after the implementation of Medicare reimbursement policy. 
Specifically, the level (intercept) was reduced by 2.13% (about a relative 50% reduction) 
but the trend (slope) did not change. Because the trends before and after the policy 
change were similar, Medicare reimbursement policy had a one-time only effect on the 
utilization of ESAs. 
 
6.1.2 Results on the Utilization of Blood Transfusions 
Figure 6.2 illustrated the change in the monthly utilization of blood transfusions 
before and after the implementation of Medicare reimbursement policy. From visual 
inspection, we found that during the pre-policy period, the monthly utilization of blood 
transfusions changed from 1.29% in January 2003 to 0.91% in June 2007 in the treatment 
group; and the monthly utilization of blood transfusions changed from 1.14% in January 
2003 to 0.90% in June 2007 in the control group. During the policy period, the monthly 
utilization of blood transfusions increased in the treatment group (from 0.88% in July 
2007 to 1.02% in April 2008); and the monthly utilization of blood transfusions increased 
in the control group (from 0.83% in July 2007 to 1.02% in April 2008). During the post-
policy period, the monthly utilization of blood transfusions changed from 1.01% in May 
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2008 to 0.96% in December 2009 in the treatment group; and the monthly utilization of 
blood transfusions changed from 1.04% in May 2008 to 0.95% in December 2009 in the 
control group.  
To quantity the change in the monthly utilization of blood transfusions before and 
after the implementation of Medicare reimbursement policy, we conducted a segmented 
regression analysis in the interrupted time-series design. Table 6.4 summarized the results 
of the change in the monthly utilization of blood transfusions before and after the 
implementation of Medicare reimbursement policy. According to the segmented 
regression analysis, in the treatment group, the monthly utilization of blood transfusions 
in the end of the pre-policy period (June 2007) and the beginning of the post-policy 
period (May 2008) was estimated as 0.89% and 0.99%, respectively. The level in the 
monthly utilization of blood transfusions was estimated to be increased by 0.10% after 
the policy change in the treatment group. In the control group, the monthly utilization of 
blood transfusions in the end of the pre-policy period (June 2007) and the beginning of 
the post-policy period (May 2008) was estimated as 0.95% and 0.95%, respectively. The 
level in the monthly utilization of blood transfusions remained the same after the policy 
change in the control group. Thus, when including the control group in the interrupted 
time-series design, the level in the monthly utilization of blood transfusions was 
increased statistically significantly by 0.10% (P = .0186) after the policy change.  
According to the segmented regression analysis, in the treatment group, the trend 
in the monthly utilization of blood transfusions in the pre- and post-policy period was 
estimated as -0.01% and 0.00%, respectively. The trend in the monthly utilization of 
blood transfusions was estimated to be increased by 0.01% after the policy change in the 
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treatment group. In the control group, the trend in the monthly utilization of blood 
transfusions in the pre- and post-policy period was estimated as 0.00% and 0.00%, 
respectively. The trend in the monthly utilization of blood transfusions was estimated to 
be the same after the policy change in the treatment group. Thus, when including the 
control group in the interrupted time-series design, the trend in the monthly utilization of 
blood transfusions was increased by 0.01% (P = .0524) after the policy change but was 
not statistically significant.  
In summary, the utilization of blood transfusions in cancer patients with 
chemotherapy-induced anemia was increased after the implementation of Medicare 
reimbursement policy. Specifically, the level (intercept) was increased by 0.10% (about a 
relative 10% increase) but the trend (slope) did not change. Because the trends before and 
after the policy change were similar, Medicare reimbursement policy had a one-time only 
effect on the utilization of blood transfusions. 
 
6.2 Results on the Risks 
After applying the inclusion and exclusion criteria in Aim 2, we identified 17,382 
incident users of ESAs during the pre- and post-policy periods, 12,892 (74.17%) and 
4,490 (25.83%), respectively. (Figure 6.3) To understand the impact of Medicare 
reimbursement policy change on the risks of cardiovascular and thrombovascular events 
associated with ESAs, we additionally required the study samples in Aim 2 to be free of 





6.2.1 Results on the Risk of MI 
After excluding 146 Medicare beneficiaries who had a diagnosis of MI one year 
before the index date, we identified 17,236 incident users of ESAs free of MI in the pre- 
and post-policy periods, 12,791 (74.21%) and 4,445 (25.79%), respectively. (Figure 6.3 
and Table 6.5) 
Table 6.5 summarized baseline characteristics of incident users of ESAs free  of 
MI one year before the index date between the pre- and post-policy periods. Except for 
age, sex, and the use of radiation therapy, all other baseline characteristics were 
statistically significantly different in incident users of ESAs between the pre- and post-
policy periods. Compared to those in the pre-policy period, incident users of ESAs in the 
post-policy period were more likely to be non-White, live in non-metropolitan areas, live 
in South, live in areas with low level of education, live in areas with low level of poverty, 
have one or more comorbidities, dead during the one-year follow-up period, have lung, 
ovarian, or prostate cancer, and not have surgery. 
During the one-year follow-up period, 147 (1.15%) and 54 (1.21%) incident users 
of ESAs developed MI in the pre- and post-policy periods, respectively. The difference 
was not statistically significant (P = .7256). In the unadjusted logistic regression analysis, 
we found that the implementation of Medicare reimbursement policy was not statistically 
significantly associated with the future development of MI (OR: 1.06; 95% CI: 0.77-
1.45). 
In the adjusted logistic regression analysis, we controlled for potential 
confounding factors at the baseline. (Table 6.6) We found that the implementation of 
Medicare reimbursement policy was still not statistically significantly associated with the 
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future development of MI (OR: 1.01; 95% CI: 0.74-1.39). Factors statistically 
significantly associated with the future development of MI included age, education, 
comorbidity, and vital status. Compared to those aged 66 and 69, incident users of ESAs 
who were aged 75 and 79 were 64% more likely to develop MI (OR: 1.64; 95% CI: 1.10-
2.43). Compared to those lived in areas with the highest level of education, incident users 
of ESAs who lived in areas with low level of education were 85% more likely to develop 
MI (OR: 1.85; 95% CI: 1.10-3.13). Compared to those without any comorbidity, incident 
users of ESAs who had a CCI of two were 70% more likely to develop MI (OR: 1.70; 
95% CI: 1.14-2.55); and incident users of ESAs who had a CCI of three or more were 
2.04 times more likely to develop MI (OR: 2.04; 95% CI: 1.26-3.31). Compared to those 
alive after the one-year follow-up period, incident users of ESAs who died during the 
one-year follow-up period were 2.40 times more likely to develop MI (OR: 2.40; 95% CI: 
1.72-3.34). 
In summary, the risk of MI associated with ESAs during the one-year follow-up 
period in cancer patients with chemotherapy-induced anemia was not changed after the 
implementation of Medicare reimbursement policy. 
 
6.2.2 Results on the Risk of Stroke 
After excluding 1,132 Medicare beneficiaries who had a diagnosis of stroke one 
year before the index date, we identified 16,250 incident users of ESAs free of stroke in 
the pre- and post-policy periods, 12,061 (74.22%) and 4,189 (25.78%), respectively. 
(Figure 6.3 and Table 6.7) 
 
44 
Table 6.7 summarized baseline characteristics of incident users of ESAs free of 
stroke one year before the index date between the pre- and post-policy periods. Except 
for age, sex, and the use of radiation therapy, all other baseline characteristics were 
statistically significantly different in incident users of ESAs between the pre- and post-
policy periods. Compared to those in the pre-policy period, incident users of ESAs in the 
post-policy period were more likely to be non-White, live in non-metropolitan areas, live 
in South, live in areas with low level of education, live in areas with low level of poverty, 
have one or more comorbidities, dead during the one-year follow-up period, have lung, 
ovarian, or prostate cancer, and not have surgery. 
During the one-year follow-up period, 704 (5.84%) and 252 (6.02%) incident 
users of ESAs developed stroke in the pre- and post-policy periods, respectively. The 
difference was not statistically significant (P = .6719). In the unadjusted logistic 
regression analysis, we found that the implementation of Medicare reimbursement policy 
was not statistically significantly associated with the future development of stroke (OR: 
1.03; 95% CI: 0.89-1.20). 
In the adjusted logistic regression analysis, we controlled for potential 
confounding factors at the baseline. (Table 6.8) We found that the implementation of 
Medicare reimbursement policy was still not statistically significantly associated with the 
future development of stroke (OR: 0.99; 95% CI: 0.84-1.15). Factors statistically 
significantly associated with the future development of stroke included age, education, 
poverty, comorbidity, vital status, and cancer type. Compared to those aged 66 and 69, 
incident users of ESAs who were aged 80 and over were 42% more likely to develop 
stroke (OR: 1.42; 95% CI: 1.16-1.74). Compared to those lived in areas with the highest 
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level of education, incident users of ESAs who lived in areas with the lowest level of 
education were 88% more likely to develop stroke (OR: 1.88; 95% CI: 1.41-2.52). 
Compared to those lived in areas with the lowest level of poverty, incident users of ESAs 
who lived in areas with the lower level of poverty were 22% less likely to develop stroke 
(OR: 0.78; 95% CI: 0.62-0.98); and incident users of ESAs who lived in areas with the 
highest level of poverty were 30% less likely to develop stroke (OR: 0.70; 95% CI: 0.51-
0.95). Compared to those without any comorbidity, incident users of ESAs who had a 
CCI of two were 25% more likely to develop stroke (OR: 1.25; 95% CI: 1.01-1.54). 
Compared to those alive after the one-year follow-up period, incident users of ESAs who 
died during the one-year follow-up period were 78% more likely to develop stroke (OR: 
1.78; 95% CI: 1.53-2.07). Compared to those had a primary diagnosis of breast cancer, 
incident users of ESAs who had a primary diagnosis of lung cancer were 36% more 
likely to develop stroke (OR: 1.36; 95% CI: 1.05-1.77); and incident users of ESAs who 
had a primary diagnosis of lymphomas were 41% more likely to develop stroke (OR: 
1.41; 95% CI: 1.06-1.89). 
In summary, the risk of stroke associated with ESAs during the one-year follow-
up period in cancer patients with chemotherapy-induced anemia was not changed after 
the implementation of Medicare reimbursement policy. 
 
6.2.3 Results on the Risk of VTE 
After excluding 3,158 Medicare beneficiaries who had a diagnosis of VTE one 
year before the index date, we identified 14,224 incident users of ESAs free of VTE in 
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the pre- and post-policy periods, 10,581 (74.39%) and 3,643 (25.61%), respectively. 
(Figure 6.3 and Table 6.9) 
Table 6.9 summarized baseline characteristics of incident users of ESAs free of 
VTE one year before the index date between the pre- and post-policy periods. Except for 
age, sex, and the use of radiation therapy, all other baseline characteristics were 
statistically significantly different in incident users of ESAs between the pre- and post-
policy periods. Compared to those in the pre-policy period, incident users of ESAs in the 
post-policy period were more likely to be non-White, live in non-metropolitan areas, live 
in South, live in areas with low level of education, live in areas with low level of poverty, 
have one or more comorbidities, dead during the one-year follow-up period, have lung, 
ovarian, or prostate cancer, and not have surgery. 
During the one-year follow-up period, 1,924 (18.18%) and 626 (17.18%) incident 
users of ESAs developed VTE in the pre- and post-policy periods, respectively. The 
difference was not statistically significant (P = .1748). In the unadjusted logistic 
regression analysis, we found that the implementation of Medicare reimbursement policy 
was not statistically significantly associated with the future development of VTE (OR: 
0.93; 95% CI: 0.85-1.03). 
In the adjusted logistic regression analysis, we controlled for potential 
confounding factors at the baseline. (Table 6.10) We found that the implementation of 
Medicare reimbursement policy was still not statistically significantly associated with the 
future development of VTE (OR: 0.93; 95% CI: 0.84-1.03). Factors statistically 
significantly associated with the future development of VTE included sex, race, region, 
poverty, vital status, and cancer type. Compared to females, incident users of ESAs who 
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were males were 15% less likely to develop VTE (OR: 0.85; 95% CI: 0.76-0.95). 
Compared to Whites, incident users of ESAs who were Black were 34% more likely to 
develop VTE (OR: 1.34; 95% CI: 1.12-1.61). Compared to those lived in West, incident 
users of ESAs who lived in Northeast were 19% more likely to develop VTE (OR: 1.19; 
95% CI: 1.04-1.37); and incident users of ESAs who lived in South were 18% more 
likely to develop VTE (OR: 1.18; 95% CI: 1.04-1.33). Compared to those lived in areas 
with the lowest level of poverty, incident users of ESAs who lived in areas with the 
highest level of poverty were 25% less likely to develop VTE (OR: 0.75; 95% CI: 0.61-
0.92). Compared to those alive after the one-year follow-up period, incident users of 
ESAs who died during the one-year follow-up period were 62% more likely to develop 
VTE (OR: 1.62; 95% CI: 1.47-1.79). Compared to those had a primary diagnosis of 
breast cancer, incident users of ESAs who had a primary diagnosis of colorectal cancer 
were 33% more likely to develop VTE (OR: 1.33; 95% CI: 1.12-1.57); and incident users 
of ESAs who had a primary diagnosis of lung cancer were 24% more likely to develop 
VTE (OR: 1.24; 95% CI: 1.06-1.46). 
In summary, the risk of VTE associated with ESAs during the one-year follow-up 
period in cancer patients with chemotherapy-induced anemia was not changed after the 
implementation of Medicare reimbursement policy. 
 
6.3 Results on the Costs 
After applying the inclusion and exclusion criteria in Aim 3, in the treatment 
group, we identified 17,382 incident users of ESAs (12,892 (74.17%) in the pre-policy 
period and 4,490 (25.83%) in the post-policy period). (Figure 6.4 and Table 6.11) In the 
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control group, we identified 3,069 incident users of ESAs (1,763 (57.45%) in the pre-
policy period and 1,306 (42.55%) in the post-policy period). (Figure 6.5 and Table 6.11). 
Table 6.11 summarized baseline characteristics of incident users of ESAs between 
the pre- and post-policy periods in the treatment and control groups. In the treatment 
group, except for age and sex, all other baseline characteristics were statistically 
significantly different in incident users of ESAs between the pre- and post-policy periods. 
Compared to those in the pre-policy period, incident users of ESAs in the post-policy 
period were more likely to be non-White, live in non-metropolitan areas, live in South, 
live in areas with low level of education, live in areas with low level of poverty, have one 
or more comorbidities, and dead during the one-year follow-up period. In the control 
group, except for region, all other baseline characteristics were similar in incident users 
of ESAs between the pre- and post-policy periods. Compared to those in the pre-policy 
period, incident users of ESAs in the post-policy period were more likely to be live in 
South or West. 
 
6.3.1 Results on the Anemia-Related Costs 
Table 6.12 summarized average anemia-related costs (including Medicare 
payment and patient cost-sharing) in incident users of ESAs between the pre- and post-
policy periods. In the treatment group, on average incident users of ESAs had anemia-
related costs of $8,153.19 (standard deviation (SD): $10,391.06) and $7,843.67 (SD: 
$13,509.89) during the one-year follow-up period in the pre- and post-policy periods, 
respectively. The difference was not statistically significant (P = .1622). For Medicare 
payment of anemia-related costs, on average incident users of ESAs had $6,794.42 (SD: 
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$9,237.05) and $6,829.34 (SD: $12,544.48) during the one-year follow-up period in the 
pre- and post-policy periods, respectively. The difference was not statistically significant 
(P = .8642). For patient cost-sharing of anemia-related costs, on average incident users of 
ESAs had $1,358.76 (SD: $1,644.45) and $1,014.33 (SD: $1,442.35) during the one-year 
follow-up period in the pre- and post-policy periods, respectively. Compared to those in 
the pre-policy period, incident users of ESAs in the post-policy period had statistically 
significant lower patient cost-sharing of anemia-related costs (P < .0001). 
Similarly, in the control group, on average incident users of ESAs had anemia-
related costs of $8,740.53 (SD: $13,761.47) and $9,282.03 (SD: $14,599.46) during the 
one-year follow-up period in the pre- and post-policy periods, respectively. The 
difference was not statistically significant (P = .2980). For Medicare payment of anemia-
related costs, on average incident users of ESAs had $7,431.68 (SD: $12,424.46) and 
$8,084.79 (SD: $13,440.04) during the one-year follow-up period in the pre- and post-
policy periods, respectively. The difference was not statistically significant (P = .1695). 
For patient cost-sharing of anemia-related costs, on average incident users of ESAs had 
$1,308.85 (SD: $1,768.06) and $1,197.24 (SD: $1,768.55) during the one-year follow-up 
period in the pre- and post-policy periods, respectively. The difference was not 
statistically significant (P = .0839). 
In the unadjusted GLM analysis, we found that the implementation of Medicare 
reimbursement policy was statistically significantly associated with a 8.98% reduction in 
anemia-related costs (P = .0389). In the adjusted GLM analysis, we controlled for 
potential confounding factors at the baseline. (Table 6.13) We found that the 
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implementation of Medicare reimbursement policy was statistically significantly 
associated with a 11.20% reduction in anemia-related costs (P = .0113). 
In Table 6.13, other factors statistically significantly associated with the change in 
anemia-related costs included age, sex, race, residence, region, education, poverty, 
comorbidity, and vital status. Compared to those aged 66 and 69, incident users of ESAs 
who were aged 70 and 74 on average had a 7.82% lower anemia-related costs (P = 
.0002); incident users of ESAs who were aged 75 and 79 on average had a 7.73% lower 
anemia-related costs (P = .0005); and incident users of ESAs who were aged 80 and over 
on average had a 16.99% lower anemia-related costs (P < .0001). Compared to females, 
incident users of ESAs who were males on average had a 8.62% higher anemia-related 
costs (P < .0001). Compared to Whites, incident users of ESAs who were Black on 
average had a 6.46% higher anemia-related costs (P = .0354). Compared to those lived in 
metropolitan areas, incident users of ESAs who lived in non-metropolitan areas on 
average had a 6.67% lower anemia-related costs (P = .0036). Compared to those lived in 
West, incident users of ESAs who lived in Northeast on average had a 4.92% higher 
anemia-related costs (P = .0349); and incident users of ESAs who lived in South on 
average had a 4.37% lower anemia-related costs (P = .0398). Compared to those lived in 
areas with the highest level of education, incident users of ESAs who lived in areas with 
the lower level of education on average had a 6.57% higher anemia-related costs (P = 
.0160) and incident users of ESAs who lived in areas with the lowest level of education 
on average had a 7.70% higher anemia-related costs (P = .0194). Compared to those lived 
in areas with the lowest level of poverty, incident users of ESAs who lived in areas with 
the higher level of poverty on average had a 5.78% lower anemia-related costs (P = 
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.0452). Compared to those without any comorbidity, incident users of ESAs who had a 
CCI of one on average had a 3.61% higher anemia-related costs (P = .0464); incident 
users of ESAs who had a CCI of two on average had a 8.44% higher anemia-related costs 
(P = .0005); and incident users of ESAs who had a CCI of three or more on average had a 
15.14% higher anemia-related costs (P < .0001). Compared to those alive after the one-
year follow-up period, incident users of ESAs who died during the one-year follow-up 
period on average had a 15.53% higher anemia-related costs (P < .0001).  
When examining Medicare payment of anemia-related costs, we found that in the 
unadjusted GLM analysis, the implementation of Medicare reimbursement policy was not 
statistically significantly associated with Medicare payment of anemia-related costs (P = 
.1123). In the adjusted GLM analysis, we controlled for potential confounding factors at 
the baseline. (Table 6.14) We found that the implementation of Medicare reimbursement 
policy was statistically significantly associated with a 9.83% reduction in Medicare 
payment of anemia-related costs (P = .0310). 
In Table 6.14, other factors statistically significantly associated with the change in 
Medicare payment of anemia-related costs included age, sex, race, residence, region, 
education, poverty, comorbidity, and vital status. Compared to those aged 66 and 69, 
incident users of ESAs who were aged 70 and 74 on average had a 8.74% lower 
Medicare payment of anemia-related costs (P < .0001); incident users of ESAs who were 
aged 75 and 79 on average had a 8.60% lower Medicare payment of anemia-related costs 
(P = .0002); and incident users of ESAs who were aged 80 and over on average had a 
17.58% lower Medicare payment of anemia-related costs (P < .0001). Compared to 
females, incident users of ESAs who were males on average had a 8.81% higher 
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Medicare payment of anemia-related costs (P < .0001). Compared to Whites, incident 
users of ESAs who were Black on average had a 6.72% higher Medicare payment of 
anemia-related costs (P = .0338). Compared to those lived in metropolitan areas, incident 
users of ESAs who lived in non-metropolitan areas on average had a 8.16% lower 
Medicare payment of anemia-related costs (P = .0006). Compared to those lived in West, 
incident users of ESAs who lived in South on average had a 5.91% lower Medicare 
payment of anemia-related costs (P = .0071). Compared to those lived in areas with the 
highest level of education, incident users of ESAs who lived in areas with the lower level 
of education on average had a 7.16% higher Medicare payment of anemia-related costs (P 
= .0108) and incident users of ESAs who lived in areas with the lowest level of education 
on average had a 9.69% higher Medicare payment of anemia-related costs (P = .0043). 
Compared to those lived in areas with the lowest level of poverty, incident users of ESAs 
who lived in areas with the higher level of poverty on average had a 7.32% lower 
Medicare payment of anemia-related costs (P = .0139) and incident users of ESAs who 
lived in areas with the highest level of poverty on average had a 7.57% lower Medicare 
payment of anemia-related costs (P = .0357). Compared to those without any 
comorbidity, incident users of ESAs who had a CCI of one on average had a 3.96% 
higher Medicare payment of anemia-related costs (P = .0338); incident users of ESAs 
who had a CCI of two on average had a 9.81% higher Medicare payment of anemia-
related costs (P < .0001); and incident users of ESAs who had a CCI of three or more on 
average had a 16.31% higher Medicare payment of anemia-related costs (P < .0001). 
Compared to those alive after the one-year follow-up period, incident users of ESAs who 
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died during the one-year follow-up period on average had a 19.71% higher Medicare 
payment of anemia-related costs (P < .0001).  
When examining patient cost-sharing of anemia-related costs, we found that in the 
unadjusted GLM analysis, the implementation of Medicare reimbursement policy was 
statistically significantly associated with a 19.14% reduction in patient cost-sharing of 
anemia-related costs (P < .0001). In the adjusted GLM analysis, we controlled for 
potential confounding factors at the baseline. (Table 6.15) We found that the 
implementation of Medicare reimbursement policy was statistically significantly 
associated with a 18.40% reduction in patient cost-sharing of anemia-related costs (P < 
.0001). 
In Table 6.15, other factors statistically significantly associated with the change in 
patient cost-sharing of anemia-related costs included age, sex, race, region, comorbidity, 
and vital status. Compared to those aged 66 and 69, incident users of ESAs who were 
aged 70 and 74 on average had a 3.96% lower patient cost-sharing of anemia-related 
costs (P = .0430); incident users of ESAs who were aged 75 and 79 on average had a 
4.00% lower patient cost-sharing of anemia-related costs (P = .0494); and incident users 
of ESAs who were aged 80 and over on average had a 14.35% lower patient cost-sharing 
of anemia-related costs (P < .0001). Compared to females, incident users of ESAs who 
were males on average had a 8.48% higher patient cost-sharing of anemia-related costs (P 
< .0001). Compared to Whites, incident users of ESAs who were other races on average 
had a 7.22% lower patient cost-sharing of anemia-related costs (P = .0197). Compared to 
those lived in West, incident users of ESAs who lived in Northeast on average had a 
9.90% higher patient cost-sharing of anemia-related costs (P < .0001); incident users of 
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ESAs who lived in Midwest on average had a 5.64% higher patient cost-sharing of 
anemia-related costs (P = .0252); and incident users of ESAs who lived in South on 
average had a 5.90% higher patient cost-sharing of anemia-related costs (P = .0026). 
Compared to those without any comorbidity, incident users of ESAs who had a CCI of 
three or more on average had a 8.70% higher patient cost-sharing of anemia-related costs 
(P = .0012). Compared to those alive after the one-year follow-up period, incident users 
of ESAs who died during the one-year follow-up period on average had a 7.75% lower 
patient cost-sharing of anemia-related costs (P < .0001).  
In summary, anemia-related costs associated with ESAs during the one-year 
follow-up period in cancer patients with chemotherapy-induced anemia were reduced by 
11.20% after the implementation of Medicare reimbursement policy. Specifically, 
Medicare payment of anemia-related costs were reduced by 9.83% and patient cost-
sharing of anemia-related costs were reduced by 18.40%. 
 
6.3.2 Results on the Total Medical Costs 
Table 6.12 summarized average total medical costs (including Medicare payment 
and patient cost-sharing) in incident users of ESAs between the pre- and post-policy 
periods. In the treatment group, on average incident users of ESAs had total medical costs 
of $58,777.49 (SD: $41,369.36) and $55,850.92 (SD: $40,494.11) during the one-year 
follow-up period in the pre- and post-policy periods, respectively. Compared to those in 
the pre-policy period, incident users of ESAs in the post-policy period had statistically 
significant lower total medical costs (P < .0001). For Medicare payment of total medical 
costs, on average incident users of ESAs had $48,845.85 (SD: $35,429.73) and 
$46,921.85 (SD: $34,962.77) during the one-year follow-up period in the pre- and post-
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policy periods, respectively. Compared to those in the pre-policy period, incident users of 
ESAs in the post-policy period had statistically significant lower Medicare payment of 
total medical costs (P = .0017). For patient cost-sharing of total medical costs, on average 
incident users of ESAs had $9,931.64 (SD: $7,365.37) and $8,929.06 (SD: $6,706.04) 
during the one-year follow-up period in the pre- and post-policy periods, respectively. 
Compared to those in the pre-policy period, incident users of ESAs in the post-policy 
period had statistically significant lower patient cost-sharing of total medical costs (P < 
.0001). 
Similarly, in the control group, on average incident users of ESAs had total 
medical costs of $51,476.36 (SD: $53,823.64) and $55,219.84 (SD: $58,325.85) during 
the one-year follow-up period in the pre- and post-policy periods, respectively. The 
difference was not statistically significant (P = .0694). For Medicare payment of total 
medical costs, on average incident users of ESAs had $44,260.17 (SD: $47,398.36) and 
$47,602.76 (SD: $50,850.23) during the one-year follow-up period in the pre- and post-
policy periods, respectively. The difference was not statistically significant (P = .0640). 
For patient cost-sharing of total medical costs, on average incident users of ESAs had 
$7,216.19 (SD: $7,440.38) and $7,617.09 (SD: $8,493.59) during the one-year follow-up 
period in the pre- and post-policy periods, respectively. The difference was not 
statistically significant (P = .1733). 
In the unadjusted GLM analysis, we found that the implementation of Medicare 
reimbursement policy was statistically significantly associated with a 12.14% reduction 
in total medical costs (P < .0001). In the adjusted GLM analysis, we controlled for 
potential confounding factors at the baseline. (Table 6.16) We found that the 
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implementation of Medicare reimbursement policy was statistically significantly 
associated with a 11.96% reduction in total medical costs (P = .0001). 
In Table 6.16, other factors statistically significantly associated with the change in 
total medical costs included age, sex, race, residence, region, education, poverty, 
comorbidity, and vital status. Compared to those aged 66 and 69, incident users of ESAs 
who were aged 70 and 74 on average had a 4.39% lower total medical costs (P = .0030); 
incident users of ESAs who were aged 75 and 79 on average had a 6.90% lower total 
medical costs (P < .0001); and incident users of ESAs who were aged 80 and over on 
average had a 15.31% lower total medical costs (P < .0001). Compared to females, 
incident users of ESAs who were males on average had a 5.41% higher total medical 
costs (P < .0001). Compared to Whites, incident users of ESAs who were Black on 
average had a 5.26% higher total medical costs (P = .0135); and incident users of ESAs 
who were other races on average had a 4.83% higher total medical costs (P = .0394). 
Compared to those lived in metropolitan areas, incident users of ESAs who lived in non-
metropolitan areas on average had a 5.97% lower total medical costs (P = .0002). 
Compared to those lived in West, incident users of ESAs who lived in Northeast on 
average had a 3.56% higher total medical costs (P = .0286); and incident users of ESAs 
who lived in South on average had a 7.89% lower total medical costs (P < .0001). 
Compared to those lived in areas with the highest level of education, incident users of 
ESAs who lived in areas with the lower level of education on average had a 3.90% higher 
total medical costs (P = .0412). Compared to those lived in areas with the lowest level of 
poverty, incident users of ESAs who lived in areas with the lower level of poverty on 
average had a 4.82% lower total medical costs (P = .0046); and incident users of ESAs 
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who lived in areas with the higher level of poverty on average had a 5.34% lower total 
medical costs (P = .0084). Compared to those without any comorbidity, incident users of 
ESAs who had a CCI of three or more on average had a 20.58% higher total medical 
costs (P < .0001). Compared to those alive after the one-year follow-up period, incident 
users of ESAs who died during the one-year follow-up period on average had a 6.04% 
lower total medical costs (P < .0001).  
When examining Medicare payment of total medical costs, we found that in the 
unadjusted GLM analysis, the implementation of Medicare reimbursement policy was 
statistically significantly associated with a 11.30% reduction in Medicare payment of 
total medical costs (P = .0003). In the adjusted GLM analysis, we controlled for potential 
confounding factors at the baseline. (Table 6.17) We found that the implementation of 
Medicare reimbursement policy was statistically significantly associated with a 11.59% 
reduction in Medicare payment of total medical costs (P = .0003). 
In Table 6.17, other factors statistically significantly associated with the change in 
Medicare payment of total medical costs included age, sex, race, residence, region, 
education, poverty, and comorbidity. Compared to those aged 66 and 69, incident users 
of ESAs who were aged 70 and 74 on average had a 4.44% lower Medicare payment of 
total medical costs (P = .0036); incident users of ESAs who were aged 75 and 79 on 
average had a 6.33% lower Medicare payment of total medical costs (P < .0001); and 
incident users of ESAs who were aged 80 and over on average had a 14.32% lower 
Medicare payment of total medical costs (P < .0001). Compared to females, incident 
users of ESAs who were males on average had a 5.16% higher Medicare payment of total 
medical costs (P < .0001). Compared to Whites, incident users of ESAs who were Black 
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on average had a 5.47% higher Medicare payment of total medical costs (P = .0126); and 
incident users of ESAs who were other races on average had a 5.01% higher Medicare 
payment of total medical costs (P = .0380). Compared to those lived in metropolitan 
areas, incident users of ESAs who lived in non-metropolitan areas on average had a 
7.09% lower Medicare payment of total medical costs (P < .0001). Compared to those 
lived in West, incident users of ESAs who lived in Northwest on average had a 3.46% 
higher Medicare payment of total medical costs (P = .0393); and incident users of ESAs 
who lived in South on average had a 8.45% lower Medicare payment of total medical 
costs (P < .0001). Compared to those lived in areas with the highest level of education, 
incident users of ESAs who lived in areas with the lower level of education on average 
had a 3.98% higher Medicare payment of total medical costs (P = .0431); and incident 
users of ESAs who lived in areas with the lowest level of education on average had a 
4.93% higher Medicare payment of total medical costs (P = .0369). Compared to those 
lived in areas with the lowest level of poverty, incident users of ESAs who lived in areas 
with the lower level of poverty on average had a 4.92% lower Medicare payment of total 
medical costs (P = .0049); and incident users of ESAs who lived in areas with the higher 
level of poverty on average had a 5.66% lower Medicare payment of total medical costs 
(P = .0066). Compared to those without any comorbidity, incident users of ESAs who 
had a CCI of three or more on average had a 21.91% higher Medicare payment of total 
medical costs (P < .0001). 
When examining patient cost-sharing of total medical costs, we found that in the 
unadjusted GLM analysis, the implementation of Medicare reimbursement policy was 
statistically significantly associated with a 16.06% reduction in patient cost-sharing of 
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total medical costs (P < .0001). In the adjusted GLM analysis, we controlled for potential 
confounding factors at the baseline. (Table 6.18) We found that the implementation of 
Medicare reimbursement policy was statistically significantly associated with a 13.58% 
reduction in patient cost-sharing of total medical costs (P < .0001). 
In Table 6.18, other factors statistically significantly associated with the change in 
patient cost-sharing of total medical costs included age, sex, region, poverty, 
comorbidity, and vital status. Compared to those aged 66 and 69, incident users of ESAs 
who were aged 70 and 74 on average had a 4.26% lower patient cost-sharing of total 
medical costs (P = .0040); incident users of ESAs who were aged 75 and 79 on average 
had a 9.70% lower patient cost-sharing of total medical costs (P < .0001); and incident 
users of ESAs who were aged 80 and over on average had a 20.32% lower patient cost-
sharing of total medical costs (P < .0001). Compared to females, incident users of ESAs 
who were males on average had a 7.46% higher patient cost-sharing of total medical 
costs (P < .0001). Compared to those lived in West, incident users of ESAs who lived in 
Northeast on average had a 4.22% higher patient cost-sharing of total medical costs (P = 
.0095); and incident users of ESAs who lived in South on average had a 4.63% lower 
patient cost-sharing of total medical costs (P = .0016). Compared to those lived in areas 
with the lowest level of poverty, incident users of ESAs who lived in areas with the lower 
level of poverty on average had a 4.18% lower patient cost-sharing of total medical costs 
(P = .0140). Compared to those without any comorbidity, incident users of ESAs who 
had a CCI of one on average had a 3.93% lower patient cost-sharing of total medical 
costs (P = .0019); incident users of ESAs who had a CCI of two on average had a 6.23% 
lower patient cost-sharing of total medical costs (P = .0002); and incident users of ESAs 
 
60 
who had a CCI of three or more on average had a 14.07% higher patient cost-sharing of 
total medical costs (P < .0001). Compared to those alive after the one-year follow-up 
period, incident users of ESAs who died during the one-year follow-up period on average 
had a 30.16% lower patient cost-sharing of total medical costs (P < .0001).  
In summary, total medical costs associated with ESAs during the one-year follow-
up period in cancer patients with chemotherapy-induced anemia were reduced by 11.96% 
after the implementation of Medicare reimbursement policy. Specifically, Medicare 
payment of total medical costs were reduced by 11.59% and patient cost-sharing of total 




Table 6.1: Total number of eligible cancer patients and percentage of patients received 
ESAs or blood transfusions in each month 
 
Month Total N 
ESAs Blood transfusions 
% % 
2003    
    January 55,719 5.23 1.29 
    February 56,503 5.02 1.14 
    March 57,412 5.23 1.29 
    April 58,206 5.31 1.19 
    May 59,077 5.53 1.25 
    June 60,002 5.53 1.14 
    July 60,979 5.76 1.24 
    August 61,750 5.60 1.17 
    September 62,621 5.60 1.18 
    October 63,551 5.64 1.26 
    November 63,974 5.16 1.08 
    December 64,592 5.46 1.17 
2004    
    January 65,367 5.28 1.23 
    February 66,022 5.13 1.17 
    March 67,031 5.63 1.26 
    April 67,814 5.42 1.11 
    May 68,458 5.48 1.09 
    June 69,308 5.81 1.14 
    July 70,141 5.59 1.14 
    August 70,982 5.65 1.19 
    September 71,821 5.54 1.05 
    October 72,537 5.14 1.16 
    November 73,185 4.97 1.12 
    December 73,762 4.99 1.03 
2005    
    January 74,521 4.77 1.04 
    February 74,990 4.70 1.05 
    March 75,780 5.04 1.15 
    April 76,264 4.98 1.03 
    May 76,942 5.02 1.08 
    June 77,674 5.14 1.06 
    July 78,381 5.02 1.11 
    August 79,161 5.19 1.11 
    September 79,593 4.96 0.96 
    October 80,152 4.75 0.99 
    November 80,775 4.85 0.92 
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    December 81,177 4.66 0.97 
2006    
    January 81,405 4.60 0.98 
    February 81,786 4.54 0.96 
    March 82,514 4.83 1.03 
    April 82,805 4.66 0.94 
    May 83,471 4.95 0.97 
    June 84,004 4.86 0.97 
    July 84,700 4.71 0.98 
    August 85,463 4.87 1.01 
    September 85,895 4.53 0.90 
    October 86,700 4.63 0.98 
    November 87,348 4.57 0.95 
    December 87,861 4.24 0.83 
2007    
    January 86,999 4.39 0.91 
    February 87,604 4.04 0.89 
    March 88,364 3.93 0.95 
    April 88,810 3.55 0.95 
    May 89,548 3.50 0.98 
    June 90,187 3.15 0.91 
    July 90,967 3.21 0.88 
    August 91,898 2.08 1.06 
    September 92,464 1.68 0.92 
    October 93,400 1.78 1.00 
    November 93,988 1.60 0.98 
    December 94,664 1.49 0.89 
2008    
    January 94,045 1.47 0.94 
    February 94,532 1.42 0.91 
    March 95,192 1.36 1.02 
    April 95,761 1.24 1.02 
    May 96,385 1.23 1.01 
    June 97,135 1.23 0.98 
    July 98,005 1.27 1.01 
    August 98,774 1.10 0.95 
    September 99,629 0.97 1.01 
    October 100,608 1.06 1.01 
    November 101,167 0.91 0.96 
    December 101,875 0.97 0.97 
2009    
    January 101,269 0.85 0.96 
    February 101,773 0.86 0.89 
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    March 102,573 0.91 1.05 
    April 103,247 0.95 1.02 
    May 103,967 0.91 1.00 
    June 104,807 0.90 1.03 
    July 105,751 0.85 1.04 
    August 106,590 0.84 0.96 
    September 107,333 0.79 0.96 
    October 108,298 0.79 1.02 
    November 108,914 0.75 0.94 
    December 109,646 0.79 0.96 
 ESAs: erythropoiesis-stimulating agents   
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Table 6.2: Total number of eligible CKD patients and percentage of patients received 
ESAs or blood transfusions in each month 
 
Month Total N 
ESAs Blood transfusions 
% % 
2003    
    January 28,684 5.68 1.14 
    February 28,952 5.54 1.03 
    March 29,275 5.60 1.02 
    April 29,570 5.53 1.00 
    May 29,944 5.49 1.09 
    June 30,232 5.50 0.93 
    July 30,672 5.64 0.94 
    August 31,055 5.58 0.99 
    September 31,481 5.51 0.97 
    October 31,903 5.60 1.06 
    November 32,234 5.44 0.95 
    December 32,572 5.50 1.12 
2004    
    January 32,892 5.47 1.09 
    February 33,138 5.46 0.96 
    March 33,531 5.63 1.12 
    April 33,825 5.63 1.05 
    May 34,168 5.56 0.92 
    June 34,546 5.57 0.96 
    July 34,899 5.58 0.99 
    August 35,339 5.50 0.93 
    September 35,732 5.62 0.96 
    October 36,175 5.42 0.96 
    November 36,457 5.45 0.95 
    December 36,872 5.38 1.10 
2005    
    January 37,265 5.40 1.06 
    February 37,510 5.35 0.98 
    March 37,848 5.39 1.04 
    April 38,093 5.36 1.07 
    May 38,433 5.33 1.04 
    June 38,783 5.41 1.00 
    July 39,133 5.32 0.91 
    August 39,569 5.43 0.98 
    September 39,517 5.34 0.91 
    October 40,211 5.28 0.99 
    November 40,913 5.21 0.96 
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    December 41,516 5.16 0.93 
2006    
    January 41,916 5.19 1.05 
    February 42,392 5.14 1.01 
    March 43,021 5.24 1.06 
    April 43,372 5.10 0.97 
    May 44,000 5.19 0.98 
    June 44,583 5.17 1.03 
    July 45,167 5.06 0.91 
    August 45,830 5.17 0.98 
    September 46,322 5.03 0.85 
    October 47,018 5.09 0.93 
    November 47,505 5.06 0.86 
    December 48,049 4.96 0.92 
2007    
    January 47,790 5.06 1.05 
    February 48,168 4.96 0.89 
    March 48,618 4.88 0.96 
    April 49,023 4.76 1.01 
    May 49,581 4.74 1.05 
    June 50,128 4.66 0.90 
    July 50,726 4.64 0.83 
    August 51,363 4.51 0.94 
    September 51,852 4.42 0.85 
    October 52,462 4.41 0.87 
    November 52,959 4.30 0.89 
    December 53,548 4.16 0.92 
2008    
    January 53,670 4.28 1.07 
    February 54,073 4.09 0.95 
    March 54,507 4.05 1.03 
    April 54,786 4.15 1.02 
    May 55,238 4.11 1.04 
    June 55,653 4.09 0.87 
    July 56,281 4.03 0.90 
    August 56,806 4.01 0.95 
    September 57,366 3.94 0.88 
    October 57,939 3.97 0.96 
    November 58,375 3.77 0.87 
    December 58,916 3.81 0.98 
2009    
    January 58,679 3.83 1.07 
    February 59,051 3.81 0.88 
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    March 59,490 3.88 0.97 
    April 59,856 3.88 0.96 
    May 60,376 3.75 0.86 
    June 60,933 3.77 0.96 
    July 61,634 3.81 0.88 
    August 62,132 3.63 0.94 
    September 62,738 3.72 0.85 
    October 63,244 3.69 0.92 
    November 63,679 3.49 0.90 
    December 64,157 3.57 0.95 
CKD: chronic kidney disease;   ESAs: erythropoiesis-stimulating agents 
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Table 6.3: Change in the monthly utilization of ESAs before and after the implementation 
of Medicare reimbursement policy 
 
 Estimate P 
Intercept 5.73 <.0001 
Month -0.01 <.0001 
Policy change -0.83 <.0001 
Month after policy change -0.01 0.1905 
Group assignment 0.06 0.5046 
Month × Group assignment -0.02 <.0001 
Policy change × Group assignment -2.13 <.0001 
Month after policy change × Group assignment 0.02 0.1366 
ESAs: erythropoiesis-stimulating agents  
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Table 6.4: Change in the monthly utilization of blood transfusions before and after the 
implementation of Medicare reimbursement policy 
 
 Estimate P 
Intercept 1.03 <.0001 
Month 0.00 0.0020 
Policy change 0.00 0.9609 
Month after policy change 0.00 0.9194 
Group assignment 0.22 <.0001 
Month × Group assignment -0.01 <.0001 
Policy change × Group assignment 0.10 0.0186 




Table 6.5: Baseline characteristics of incident users of ESAs free of MI one year before 









    66-69 26.77 25.94 
 
    70-74 30.00 29.74 
 
    75-79 23.84 25.53 
 





    Male 39.73 40.11 
 





    White 88.34 86.68 
 
    Black 6.67 7.22 
 





    Metropolitan 83.26 81.06 
 





    Northeast 21.66 20.72 
 
    Midwest 11.95 11.50 
 
    South 27.53 30.55 
 





    1st quartile 25.37 24.03 
 
    2nd quartile 25.31 23.91 
 
    3rd quartile 25.22 25.51 
 





    1st quartile 25.42 24.58 
 
    2nd quartile 25.47 23.86 
 
    3rd quartile 24.74 25.22 
 





    0 50.52 44.39 
 
    1 31.69 35.21 
 
    2 12.31 13.23 
 





    Alive 56.19 52.13 
 
    Dead 43.81 47.87 
 






    Breast cancer 19.97 18.74 
 
    Colorectal cancer 15.44 10.66 
 
    Lung cancer 38.12 42.18 
 
    Lymphomas 12.70 12.64 
 
    Ovarian cancer 4.66 5.76 
 





    Yes 50.35 42.25 
 
    No 48.58 56.81 
 





    Yes 35.45 36.76 
 
    No 62.61 61.08 
 
    Unknown 1.94 2.16   
ESAs: erythropoiesis-stimulating agents;   MI: myocardial infarction;   CCI: Charlson 
comorbidity index  
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Table 6.6: Adjusted logistic regression analysis on factors associated with the future 
development of MI 
 
  OR 95% CI 
Policy change 
   
    Pre-policy period Ref 
      Post-policy period 1.01 0.74 1.39 
Age 
       66-69 Ref 
      70-74 0.89 0.58 1.37 
    75-79 1.64 1.10 2.43 
    80+ 1.31 0.84 2.05 
Sex 
       Male 0.96 0.69 1.33 
    Female Ref 
  Race 
       White Ref 
      Black 1.20 0.68 2.10 
    Other 0.67 0.30 1.46 
Residence 
       Metropolitan Ref 
      Non-metropolitan 1.15 0.77 1.72 
Region 
       Northeast 0.96 0.63 1.47 
    Midwest 0.88 0.53 1.45 
    South 0.86 0.58 1.28 
    West Ref 
  Education 
       1st quartile Ref 
      2nd quartile 1.53 0.97 2.41 
    3rd quartile 1.85 1.10 3.13 
    4th quartile 1.82 0.97 3.41 
Poverty 
       1st quartile Ref 
      2nd quartile 0.74 0.47 1.16 
    3rd quartile 0.61 0.36 1.06 
    4th quartile 0.63 0.33 1.19 
CCI 
       0 Ref 
      1 1.11 0.78 1.57 
    2 1.70 1.14 2.55 
    3+ 2.04 1.26 3.31 
Vital status 
       Alive Ref 




       Breast cancer Ref 
      Colorectal cancer 0.69 0.36 1.34 
    Lung cancer 1.37 0.79 2.39 
    Lymphomas 1.18 0.62 2.25 
    Ovarian cancer 0.53 0.18 1.57 
    Prostate cancer 1.08 0.52 2.25 
Surgery 
       Yes 0.95 0.65 1.39 
    No Ref 
      Unknown 0.99 0.23 4.20 
Radiation therapy 
       Yes 0.81 0.59 1.11 
    No Ref 
      Unknown 0.82 0.25 2.69 
MI: myocardial infarction;   OR: odds ratio;   CI: confidence interval;   CCI: Charlson 
comorbidity index  
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Table 6.7: Baseline characteristics of incident users of ESAs free of stroke one year 









    66-69 27.05 26.21 
 
    70-74 30.08 29.86 
 
    75-79 23.82 25.28 
 





    Male 39.36 40.18 
 





    White 88.39 86.99 
 
    Black 6.64 6.85 
 





    Metropolitan 83.27 80.76 
 





    Northeast 21.61 20.53 
 
    Midwest 12.01 11.15 
 
    South 27.41 30.72 
 





    1st quartile 25.37 24.29 
 
    2nd quartile 25.43 23.82 
 
    3rd quartile 25.24 25.10 
 





    1st quartile 25.46 24.82 
 
    2nd quartile 25.35 23.69 
 
    3rd quartile 24.85 25.08 
 





    0 52.41 45.76 
 
    1 31.27 34.95 
 
    2 11.62 12.94 
 





    Alive 56.78 52.90 
 
    Dead 43.22 47.10 
 






    Breast cancer 20.26 19.00 
 
    Colorectal cancer 15.70 10.77 
 
    Lung cancer 37.56 41.85 
 
    Lymphomas 12.70 12.53 
 
    Ovarian cancer 4.67 5.92 
 





    Yes 50.92 42.85 
 
    No 48.06 56.17 
 





    Yes 35.34 36.50 
 
    No 62.70 61.35 
 
    Unknown 1.97 2.15   
ESAs: erythropoiesis-stimulating agents;   CCI: Charlson comorbidity index  
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Table 6.8: Adjusted logistic regression analysis on factors associated with the future 
development of stroke 
 
  OR 95% CI 
Policy change 
   
    Pre-policy period Ref 
      Post-policy period 0.99 0.84 1.15 
Age 
       66-69 Ref 
      70-74 1.15 0.95 1.39 
    75-79 1.08 0.88 1.31 
    80+ 1.42 1.16 1.74 
Sex 
       Male 0.93 0.79 1.09 
    Female Ref 
  Race 
       White Ref 
      Black 1.22 0.94 1.59 
    Other 0.88 0.63 1.23 
Residence 
       Metropolitan Ref 
      Non-metropolitan 1.04 0.85 1.26 
Region 
       Northeast 1.11 0.90 1.37 
    Midwest 1.22 0.97 1.55 
    South 0.99 0.82 1.20 
    West Ref 
  Education 
       1st quartile Ref 
      2nd quartile 1.19 0.95 1.48 
    3rd quartile 1.25 0.97 1.61 
    4th quartile 1.88 1.41 2.52 
Poverty 
       1st quartile Ref 
      2nd quartile 0.78 0.62 0.98 
    3rd quartile 0.85 0.65 1.10 
    4th quartile 0.70 0.51 0.95 
CCI 
       0 Ref 
      1 1.13 0.96 1.32 
    2 1.25 1.01 1.54 
    3+ 1.27 0.95 1.69 
Vital status 
       Alive Ref 




       Breast cancer Ref 
      Colorectal cancer 0.89 0.67 1.18 
    Lung cancer 1.36 1.05 1.77 
    Lymphomas 1.41 1.06 1.89 
    Ovarian cancer 0.95 0.63 1.41 
    Prostate cancer 1.25 0.89 1.77 
Surgery 
       Yes 1.05 0.87 1.25 
    No Ref 
      Unknown 0.91 0.45 1.84 
Radiation therapy 
       Yes 0.99 0.85 1.15 
    No Ref 
      Unknown 1.05 0.64 1.74 
OR: odds ratio;   CI: confidence interval;   CCI: Charlson comorbidity index  
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Table 6.9: Baseline characteristics of incident users of ESAs free of VTE one year before 









    66-69 27.03 25.94 
 
    70-74 30.28 29.98 
 
    75-79 23.51 25.09 
 





    Male 39.60 40.30 
 





    White 88.49 86.77 
 
    Black 6.40 6.97 
 





    Metropolitan 82.79 80.46 
 





    Northeast 21.08 20.18 
 
    Midwest 11.60 10.98 
 
    South 27.85 30.69 
 





    1st quartile 24.88 24.08 
 
    2nd quartile 25.73 23.82 
 
    3rd quartile 25.12 25.24 
 





    1st quartile 24.88 23.91 
 
    2nd quartile 25.51 24.25 
 
    3rd quartile 25.29 25.21 
 





    0 52.37 46.03 
 
    1 31.41 35.44 
 
    2 11.40 12.46 
 





    Alive 57.89 53.34 
 
    Dead 42.11 46.66 
 






    Breast cancer 21.41 19.74 
 
    Colorectal cancer 13.17 9.61 
 
    Lung cancer 39.17 42.44 
 
    Lymphomas 12.68 12.46 
 
    Ovarian cancer 4.24 5.30 
 





    Yes 49.98 41.61 
 
    No 48.91 57.43 
 





    Yes 36.61 37.72 
 
    No 61.48 60.01 
 
    Unknown 1.91 2.28   
ESAs: erythropoiesis-stimulating agents;   VTE: venous thromboembolism;   CCI: 
Charlson comorbidity index  
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Table 6.10: Adjusted logistic regression analysis on factors associated with the future 
development of VTE 
 
  OR 95% CI   
Policy change 
   
    Pre-policy period Ref 
      Post-policy period 0.93 0.84 1.03 
Age 
       66-69 Ref 
      70-74 1.03 0.92 1.16 
    75-79 1.11 0.98 1.26 
    80+ 0.98 0.85 1.12 
Sex 
       Male 0.85 0.76 0.95 
    Female Ref 
  Race 
       White Ref 
      Black 1.34 1.12 1.61 
    Other 0.88 0.71 1.10 
Residence 
       Metropolitan Ref 
      Non-metropolitan 0.93 0.82 1.06 
Region 
       Northeast 1.19 1.04 1.37 
    Midwest 1.10 0.94 1.28 
    South 1.18 1.04 1.33 
    West Ref 
  Education 
       1st quartile Ref 
      2nd quartile 1.03 0.90 1.17 
    3rd quartile 0.99 0.85 1.16 
    4th quartile 0.98 0.81 1.18 
Poverty 
       1st quartile Ref 
      2nd quartile 0.96 0.84 1.10 
    3rd quartile 0.87 0.74 1.03 
    4th quartile 0.75 0.61 0.92 
CCI 
       0 Ref 
      1 0.96 0.87 1.06 
    2 0.98 0.84 1.13 
    3+ 1.05 0.85 1.28 
Vital status 
       Alive Ref 




       Breast cancer Ref 
      Colorectal cancer 1.33 1.12 1.57 
    Lung cancer 1.24 1.06 1.46 
    Lymphomas 1.19 0.99 1.44 
    Ovarian cancer 1.16 0.91 1.47 
    Prostate cancer 1.17 0.93 1.46 
Surgery 
       Yes 1.05 0.93 1.19 
    No Ref 
      Unknown 1.12 0.73 1.74 
Radiation therapy 
       Yes 0.94 0.85 1.04 
    No Ref 
      Unknown 0.74 0.51 1.07 
VTE: venous thromboembolism;   OR: odds ratio;   CI: confidence interval;   CCI: 










N = 17,382 
 Control group 




 Pre-policy Post-policy 
P N = 12,892 N = 4,490  N = 1,763 N = 1,306 






    66-69 26.72 25.75 
 
 14.97 15.16 
 
    70-74 29.94 29.82 
 
 18.49 17.92 
 
    75-79 23.95 25.55 
 
 24.33 21.82 
 
    80+ 19.39 18.89 
 







    Male 39.87 40.33 
 
 45.09 43.87 
 
    Female 60.13 59.67 
 







    White 88.37 86.70 
 
 75.53 74.00 
 
    Black 6.65 7.22 
 
 13.57 14.65 
 
    Other 4.97 6.08 
 







    Metropolitan 83.20 80.96 
 
 85.41 82.91 
 
    Non-metropolitan 16.80 19.04 
 







    Northeast 21.68 20.76 
 
 22.12 18.15 
 
    Midwest 11.98 11.43 
 
 11.51 10.87 
 
    South 27.54 30.58 
 
 27.96 31.09 
 
    West 38.79 37.24 
 







    1st quartile 25.37 24.03 
 
 21.77 19.94 
 
    2nd quartile 25.28 23.91 
 







    3rd quartile 25.23 25.42 
 
 25.10 24.32 
 
    4th quartile 24.13 26.64 
 







    1st quartile 25.43 24.59 
 
 22.76 20.10 
 
    2nd quartile 25.45 23.82 
 
 23.23 23.92 
 
    3rd quartile 24.72 25.23 
 
 23.99 24.32 
 
    4th quartile 24.40 26.36 
 







    0 50.16 43.96 
 
 21.10 19.60 
 
    1 31.61 35.19 
 
 23.37 25.34 
 
    2 12.46 13.41 
 
 23.60 21.98 
 
    3+ 5.77 7.44 
 







    Alive 56.14 51.94 
 
 76.97 76.72 
 
    Dead 43.86 48.06    23.03 23.28   










N = 17,382 
 Control group 




 Pre-policy Post-policy 
P N = 12,892 N = 4,490  N = 1,763 N = 1,306 
Mean SD Mean SD  Mean SD Mean SD 
Anemia-related costs 8,153.19 10,391.06 7,843.67 13,509.89 0.1622  8,740.53 13,761.47 9,282.03 14,599.46 0.2980 
    Medicare payment 6,794.42 9,237.05 6,829.34 12,544.48 0.8642  7,431.68 12,424.46 8,084.79 13,440.04 0.1695 
    Patient cost-sharing 1,358.76 1,644.45 1,014.33 1,442.35 <.0001  1,308.85 1,768.06 1,197.24 1,768.55 0.0839 
            
Total medical costs 58,777.49 41,369.36 55,850.92 40,494.11 <.0001  51,476.36 53,823.64 55,219.84 58,325.85 0.0694 
    Medicare payment 48,845.85 35,429.73 46,921.85 34,962.77 0.0017  44,260.17 47,398.36 47,602.76 50,850.23 0.0640 
    Patient cost-sharing 9,931.64 7,365.37 8,929.06 6,706.04 <.0001  7,216.19 7,440.38 7,617.09 8,493.59 0.1733 
ESAs: erythropoiesis-stimulating agents;   SD: standard deviation 
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Table 6.13: Change in anemia-related costs before and after the implementation of 
Medicare reimbursement policy 
 
  Estimate P 
Intercept 9.0831 <.0001 
Policy change 
  
    Pre-policy period Ref 
     Post-policy period 0.0512 0.1984 
Group assignment 
      Control group Ref 
     Treatment group -0.0677 0.0234 
Policy change × Group assignment 
  
    Otherwise Ref 
     Post-policy period and treatment group -0.1120 0.0113 
Age 
      66-69 Ref 
     70-74 -0.0782 0.0002 
    75-79 -0.0773 0.0005 
    80+ -0.1699 <.0001 
Sex 
      Male 0.0862 <.0001 
    Female Ref 
 Race 
      White Ref 
     Black 0.0646 0.0354 
    Other -0.0187 0.5788 
Residence 
      Metropolitan Ref 
     Non-metropolitan -0.0667 0.0036 
Region 
      Northeast 0.0492 0.0349 
    Midwest -0.0048 0.8601 
    South -0.0437 0.0398 
    West Ref 
 Education 
      1st quartile Ref 
     2nd quartile -0.0069 0.7694 
    3rd quartile 0.0657 0.0160 
    4th quartile 0.0770 0.0194 
Poverty 
      1st quartile Ref 
     2nd quartile -0.0413 0.0887 
    3rd quartile -0.0578 0.0452 
    4th quartile -0.0622 0.0753 




      0 Ref 
     1 0.0361 0.0464 
    2 0.0844 0.0005 
    3+ 0.1514 <.0001 
Vital status 
      Alive Ref 
     Dead 0.1553 <.0001 
CCI: Charlson comorbidity index  
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Table 6.14: Change in Medicare payment of anemia-related costs before and after the 
implementation of Medicare reimbursement policy 
 
  Estimate P 
Intercept 8.8665 <.0001 
Policy change 
  
    Pre-policy period Ref 
     Post-policy period 0.0734 0.0736 
Group assignment 
      Control group Ref 
     Treatment group -0.0882 0.0042 
Policy change × Group assignment 
  
    Otherwise Ref 
     Post-policy period and treatment group -0.0983 0.0310 
Age 
      66-69 Ref 
     70-74 -0.0874 <.0001 
    75-79 -0.0860 0.0002 
    80+ -0.1758 <.0001 
Sex 
      Male 0.0881 <.0001 
    Female Ref 
 Race 
      White Ref 
     Black 0.0672 0.0338 
    Other -0.0099 0.7761 
Residence 
      Metropolitan Ref 
     Non-metropolitan -0.0816 0.0006 
Region 
      Northeast 0.0416 0.0837 
    Midwest -0.0165 0.5575 
    South -0.0591 0.0071 
    West Ref 
 Education 
      1st quartile Ref 
     2nd quartile -0.0046 0.8504 
    3rd quartile 0.0716 0.0108 
    4th quartile 0.0969 0.0043 
Poverty 
      1st quartile Ref 
     2nd quartile -0.0465 0.0626 
    3rd quartile -0.0732 0.0139 
    4th quartile -0.0757 0.0357 




      0 Ref 
     1 0.0396 0.0338 
    2 0.0981 <.0001 
    3+ 0.1631 <.0001 
Vital status 
      Alive Ref 
     Dead 0.1971 <.0001 
CCI: Charlson comorbidity index  
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Table 6.15: Change in patient cost-sharing of anemia-related costs before and after the 
implementation of Medicare reimbursement policy 
 
  Estimate P 
Intercept 7.1513 <.0001 
Policy change  
 
    Pre-policy period Ref 
     Post-policy period -0.0898 0.0143 
Group assignment  
     Control group Ref 
     Treatment group 0.0512 0.0619 
Policy change × Group assignment  
 
    Otherwise Ref 
     Post-policy period and treatment group -0.1840 <.0001 
Age  
     66-69 Ref 
     70-74 -0.0396 0.0430 
    75-79 -0.0400 0.0494 
    80+ -0.1435 <.0001 
Sex  
     Male 0.0848 <.0001 
    Female Ref 
 Race  
     White Ref 
     Black 0.0386 0.1706 
    Other -0.0722 0.0197 
Residence  
     Metropolitan Ref 
     Non-metropolitan 0.0161 0.4440 
Region  
     Northeast 0.0990 <.0001 
    Midwest 0.0564 0.0252 
    South 0.0590 0.0026 
    West Ref 
 Education  
     1st quartile Ref 
     2nd quartile -0.0110 0.6156 
    3rd quartile 0.0381 0.1333 
    4th quartile -0.0315 0.3014 
Poverty  
     1st quartile Ref 
     2nd quartile -0.0168 0.4559 
    3rd quartile 0.0205 0.4438 
    4th quartile 0.0064 0.8435 




     0 Ref 
     1 0.0272 0.1027 
    2 0.0068 0.7597 
    3+ 0.0870 0.0012 
Vital status  
     Alive Ref 
     Dead -0.0775 <.0001 
CCI: Charlson comorbidity index  
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Table 6.16: Change in total medical costs before and after the implementation of 
Medicare reimbursement policy 
 
  Estimate P 
Intercept 10.8772 <.0001 
Policy change 
  
    Pre-policy period Ref 
     Post-policy period 0.0648 0.0195 
Group assignment 
      Control group Ref 
     Treatment group 0.1914 <.0001 
Policy change × Group assignment 
  
    Otherwise Ref 
     Post-policy period and treatment group -0.1196 0.0001 
Age 
      66-69 Ref 
     70-74 -0.0439 0.0030 
    75-79 -0.0690 <.0001 
    80+ -0.1531 <.0001 
Sex 
      Male 0.0541 <.0001 
    Female Ref 
 Race 
      White Ref 
     Black 0.0526 0.0135 
    Other 0.0483 0.0394 
Residence 
      Metropolitan Ref 
     Non-metropolitan -0.0597 0.0002 
Region 
      Northeast 0.0356 0.0286 
    Midwest -0.0092 0.6261 
    South -0.0789 <.0001 
    West Ref 
 Education 
      1st quartile Ref 
     2nd quartile -0.0193 0.2419 
    3rd quartile 0.0390 0.0412 
    4th quartile 0.0441 0.0548 
Poverty 
      1st quartile Ref 
     2nd quartile -0.0482 0.0046 
    3rd quartile -0.0534 0.0084 
    4th quartile -0.0352 0.1492 




      0 Ref 
     1 -0.0025 0.8412 
    2 0.0058 0.7306 
    3+ 0.2058 <.0001 
Vital status 
      Alive Ref 
     Dead -0.0604 <.0001 
CCI: Charlson comorbidity index  
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Table 6.17: Change in Medicare payment of total medical costs before and after the 
implementation of Medicare reimbursement policy 
 
  Estimate P 
Intercept 10.7021 <.0001 
Policy change 
  
    Pre-policy period Ref 
     Post-policy period 0.0693 0.0152 
Group assignment 
      Control group Ref 
     Treatment group 0.1600 <.0001 
Policy change × Group assignment 
  
    Otherwise Ref 
     Post-policy period and treatment group -0.1159 0.0003 
Age 
      66-69 Ref 
     70-74 -0.0444 0.0036 
    75-79 -0.0633 <.0001 
    80+ -0.1432 <.0001 
Sex 
      Male 0.0516 <.0001 
    Female Ref 
 Race 
      White Ref 
     Black 0.0547 0.0126 
    Other 0.0501 0.0380 
Residence 
      Metropolitan Ref 
     Non-metropolitan -0.0709 <.0001 
Region 
      Northeast 0.0346 0.0393 
    Midwest -0.0157 0.4226 
    South -0.0845 <.0001 
    West Ref 
 Education 
      1st quartile Ref 
     2nd quartile -0.0203 0.2314 
    3rd quartile 0.0398 0.0431 
    4th quartile 0.0493 0.0369 
Poverty 
      1st quartile Ref 
     2nd quartile -0.0492 0.0049 
    3rd quartile -0.0566 0.0066 
    4th quartile -0.0368 0.1426 




      0 Ref 
     1 0.0049 0.7038 
    2 0.0185 0.2849 
    3+ 0.2191 <.0001 
Vital status 
      Alive Ref 
     Dead -0.0150 0.1932 
CCI: Charlson comorbidity index  
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Table 6.18: Change in patient cost-sharing of total medical costs before and after the 
implementation of Medicare reimbursement policy 
 
  Estimate P 
Intercept 9.0243 <.0001 
Policy change 
  
    Pre-policy period Ref 
     Post-policy period 0.0391 0.1591 
Group assignment 
      Control group Ref 
     Treatment group 0.3646 <.0001 
Policy change × Group assignment 
  
    Otherwise Ref 
     Post-policy period and treatment group -0.1358 <.0001 
Age 
      66-69 Ref 
     70-74 -0.0426 0.0040 
    75-79 -0.0970 <.0001 
    80+ -0.2032 <.0001 
Sex 
      Male 0.0746 <.0001 
    Female Ref 
 Race 
      White Ref 
     Black 0.0390 0.0667 
    Other 0.0389 0.0963 
Residence 
      Metropolitan Ref 
     Non-metropolitan -0.0014 0.9302 
Region 
      Northeast 0.0422 0.0095 
    Midwest 0.0225 0.2362 
    South -0.0463 0.0016 
    West Ref 
 Education 
      1st quartile Ref 
     2nd quartile -0.0117 0.4803 
    3rd quartile 0.0364 0.0580 
    4th quartile 0.0179 0.4367 
Poverty 
      1st quartile Ref 
     2nd quartile -0.0418 0.0140 
    3rd quartile -0.0383 0.0600 
    4th quartile -0.0254 0.3000 




      0 Ref 
     1 -0.0393 0.0019 
    2 -0.0623 0.0002 
    3+ 0.1407 <.0001 
Vital status 
      Alive Ref 
     Dead -0.3016 <.0001 








Figure 6.1: Change in the monthly utilization of ESAs before and after the implementation of Medicare reimbursement policy      








Figure 6.2: Change in the monthly utilization of blood transfusions before and after the implementation of Medicare reimbursement 
policy                                                                                                                                                                                                    








Figure 6.3: Flow chart of sample selection in Aim 2                                                                                                                           
Primary diagnosis of 
breast cancer 
N = 419,337 
Primary diagnosis of 
colorectal cancer 
N = 305,216 
Primary diagnosis of 
lung cancer 
N = 351,011 
Primary diagnosis of 
lymphomas 
N = 110,194 
Primary diagnosis of 
ovarian cancer 
N = 37,839 
Primary diagnosis of 
prostate cancer 
N = 512,381 
Primary diagnosis of six types of cancer 
N = 1,735,978 
First ESA claim in the SEER-Medicare population 
N = 48,353 
 Did not receive chemotherapy after cancer diagnosis 
 Did not initiate ESAs after chemotherapy 
 Did not initiate ESAs during the study period 
First ESA claim in the cancer population 
N = 21,507 
 Eligible for Medicare not because of age  
 Eligible for Medicare because of ESRD 
 Had a diagnosis of CKD 
First ESA claim with Medicare claims 
N = 17,913 
 Aged 65 years or younger 
 Enrolled in HMO plans 
 Did not have coverage of both Medicare Part A and B 
Incident users of ESAs 
N = 17,382 
 Receive ESAs one year before the index date 
Incident users of 
ESAs free of MI 
N = 17,236 
 Had a diagnosis 
of MI one year 
before index date 
Incident users of 
ESAs free of stroke 
N = 16,250 
 Had a diagnosis 
of stroke one year 
before index date 
Incident users of 
ESAs free of VTE 
N = 14,224 
 Had a diagnosis 
of VTE one year 











(ESAs: erythropoiesis-stimulating agents;   SEER: Surveillance, Epidemiology, and End Results;   ESRD: end-stage renal disease;   











Figure 6.4: Flow chart of sample selection of the treatment group in Aim 3                                                                                     
(ESAs: erythropoiesis-stimulating agents;   SEER: Surveillance, Epidemiology, and End Results;   ESRD: end-stage renal disease;   
CKD: chronic kidney disease;   HMO: health maintenance organization) 
Primary diagnosis of 
breast cancer 
N = 419,337 
Primary diagnosis of 
colorectal cancer 
N = 305,216 
Primary diagnosis of 
lung cancer 
N = 351,011 
Primary diagnosis of 
lymphomas 
N = 110,194 
Primary diagnosis of 
ovarian cancer 
N = 37,839 
Primary diagnosis of 
prostate cancer 
N = 512,381 
Primary diagnosis of six types of cancer 
N = 1,735,978 
First ESA claim in the SEER-Medicare population 
N = 48,353 
 Did not receive chemotherapy after cancer diagnosis 
 Did not initiate ESAs after chemotherapy 
 Did not initiate ESAs during the study period 
First ESA claim in the cancer population 
N = 21,507 
 Eligible for Medicare not because of age  
 Eligible for Medicare because of ESRD 
 Had a diagnosis of CKD 
First ESA claim with Medicare claims 
N = 17,913 
 Aged 65 years or younger 
 Enrolled in HMO plans 
 Did not have coverage of both Medicare Part A and B 
Incident users of ESAs 
N = 17,382 













Figure 6.5: Flow chart of sample selection of the control group in Aim 3                                                                                         
(SEER: Surveillance, Epidemiology, and End Results;   ESRD: end-stage renal disease;   CKD: chronic kidney disease;   ESAs: 
erythropoiesis-stimulating agents;   HMO: health maintenance organization) 
CKD population 
N = 193,155 
First ESA claim in the CKD population 
N = 6,020 
 Did not initiate ESAs after CKD diagnosis 
 Did not initiate ESAs during the study period 
First ESA claim with Medicare claims 
N = 3,366 
 Aged 65 years or younger 
 Enrolled in HMO plans 
 Did not have coverage of both Medicare Part A and B 
Incident users of ESAs 
N = 3,069 
 Receive ESAs one year before the index date 
Non-cancer cohort of the SEER-Medicare population 
N = 784,984 
 Eligible for Medicare not because of ESRD 
 Did not have a diagnosis of CKD 







  CHAPTER 7
DISSCUSION 
 
7.1 Discussion on the Utilization 
Results on the impact of Medicare reimbursement policy change on the utilization 
of ESAs in cancer patients with chemotherapy-induced anemia found in the study were 
similar to findings in some of previous studies. Through analyzing Medicare claims data, 
Arneson et al. and Hershman et al. found that the utilization of ESAs had a 51% to 57% 
reduction after the implementation of Medicare reimbursement policy, which were 
similar to the 50% reduction found in this study.75,76 Studies conducted by Hess et al. and 
Henry et al. analyzed medical records and found that the utilization of ESAs had a 29% 
to 36% reduction after the implementation of Medicare reimbursement policy, which 
were lower than the 50% reduction found in this study.73,74 Using medical records in local 
settings might only reflect the impact of the policy change at the local level instead of the 
national level. This study used the SEER-Medicare linked database (a nationally 
representative database) and could provide national estimates on the impact of Medicare 
reimbursement policy change on the utilization of ESAs. 
Results on the impact of Medicare reimbursement policy change on the utilization 
of blood transfusions in cancer patients with chemotherapy-induced anemia found in the 
study were different from findings in previous studies. Through analyzing Medicare 
claims data, Arneson et al. and Hershman et al. found that the utilization of blood 
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transfusions did not change after the implementation of Medicare reimbursement policy, 
which were different from the 10% increase found in this study.75,76 Unlike the utilization 
of ESAs, the impact of the policy change on the utilization of blood transfusions was 
indirect and unintended. The policy change might have a delayed effect on the utilization 
of blood transfusions. Arneson et al. and Hershman et al. only examined the utilization of 
blood transfusions until November 2007 and December 2008, respectively.75,76 Their 
post-policy periods might be not long enough to observe the delayed effect of the policy 
change on the utilization of blood transfusions. This study included the complete pre- and 
post-policy periods which enabled us to examine both the short-term and long-term 
effects of the policy change. The study conducted by Hess et al. analyzed medical records 
and found that the utilization of blood transfusions had a 31% increase after the 
implementation of Medicare reimbursement policy, which was higher than the 10% 
increase found in this study.73 Using medical records in local settings might only reflect 
the impact of the policy change at the local level instead of the national level. This study 
used the SEER-Medicare linked database (a nationally representative database) and could 
provide national estimates on the impact of Medicare reimbursement policy change on 
the utilization of blood transfusions. 
After the implementation of Medicare reimbursement policy, we found that the 
increase in the utilization of blood transfusions was smaller than the decrease in the 
utilization of ESAs. Three reasons can be used to explain this finding. First, unreasonable 
or unnecessary use of ESAs was reduced after the policy change. The goal of Medicare 
reimbursement policy change was to reduce unsafe use of ESAs. Patients receiving 
unreasonable or unnecessary ESA treatments did not require blood transfusions to treat 
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anemia. Second, some patients eligible for the administration of ESAs were not eligible 
for the transfusion of red blood cells. For example, when patients were severely ill, even 
though they did not have access to ESA treatment, they would not seek for blood 
transfusions. Third, some patients were worried about adverse events (e.g. 
immunosuppression and transfusion reactions) associated with blood transfusions. When 
physicians recommended blood transfusions to them, they might refuse to get transfusion 
of red blood cells. 
This study clearly distinguished among the pre-policy, policy, and post-policy 
periods. The post-policy periods defined in the previous studies were problematic.73-76,78 
All of them included some months of the policy period, the period between July 2007 and 
April 2008, in their post-policy periods. Even though Medicare reimbursement policy 
change was issued on July 30, 2007, it was not fully implemented until April 7, 2008. 
During the policy period, Medicare contractors were not required to review ESA claims 
and Medicare would not deny payment of ESA services. Thus, we would still have some 
claims of unreasonable or unnecessary ESA use (when the hemoglobin level was ≥ 10 
g/dL or the hematocrit level was ≥ 30%) during the policy period. Including part of the 
policy implementation period in the post-policy period in the analysis might 
underestimate the true impact of the policy change on the utilization of ESAs and blood 
transfusions. Thus, by defining the pre-policy, policy, and post-policy periods correctly, 
results of this study were more valid than the previous studies. 
A policy could cause two types of change on the utilization of ESAs or blood 
transfusions: the change in the level and the change in the trend. A policy might have 
both, either, or neither of these two types of change. Previous studies examined the 
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average monthly or annual utilization of ESAs and blood transfusions in the pre- and 
post-policy periods.73-76 These studies examined the change in the level of utilization 
only; the change in the trend of utilization was not captured. This study used the 
interrupted time series design, which enabled us to examine two types of change. By 
using the segmented regression analysis, the change in the level of utilization could be 
measured by the difference in the intercepts and the change in the trend of utilization 
could be measured by the difference in the slopes. 
This study incorporated a control group when examining the impact of Medicare 
reimbursement policy change on the utilization of ESAs and blood transfusions. All 
published studies did not include control groups and thus subjected to threats to internal 
validity.73-76,78 In this study, after including the control group, we concluded that the level 
in the monthly utilization of ESAs was reduced by 2.13% (about a relative 50% 
reduction) after the policy change. If the control group was not included, on the other 
hand, we could have concluded that the level in the monthly utilization of ESAs was 
reduced by 2.96% (about a relative 70% reduction) after the policy change. Thus, without 
the control group, we could have overestimated the impact of Medicare reimbursement 
policy on the utilization of ESAs. 
 
7.2 Discussion on the Risks 
 Results on the impact of Medicare reimbursement policy change on the risks of 
cardiovascular and thrombovascular events associated with ESAs in cancer patients with 
chemotherapy-induced anemia found in the study were different from what we 
hypothesized. We hypothesized that in incident users of ESAs with chemotherapy-
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induced anemia, compared to patients who initiated ESAs before the policy change, those 
who initiated ESAs after the policy change were less likely to develop MI, stroke, and 
VTE. However, this study found that the risks of MI, stroke, and VTE associated with 
ESAs during the one-year follow-up period in cancer patients with chemotherapy-
induced anemia was not changed after the implementation of Medicare reimbursement 
policy. 
 Several factors should be considered to interpret the results. First, the clinical 
evidence on the association between the hemoglobin level and the risks of cardiovascular 
and thrombovascular events in incident users of ESAs with chemotherapy-induced 
anemia was not clear. According to individual randomized control trials (RCTs) and 
literature-based meta-analyses, a target hemoglobin level completely free of increased 
risks of cardiovascular and thrombovascular events could not be identified.16,22,28,29,36,37,89-
91 CMS, FDA, and ASCO/ASH had different requirements on the appropriate 
hemoglobin level of ESA treatment in cancer patients. FDA labeling required to initiate 
ESA treatment only when the hemoglobin level was < 10 g/dL; but the hemoglobin level 
in the following administration of ESAs was not specified.42,43 The ASCO/ASH 
guidelines recommended to initiate ESA therapy when the hemoglobin level was < 10 
g/dL; but could not determine whether to initiate ESA therapy when the hemoglobin level 
was ≥ 10 g/dL but < 12 g/dL; and the target hemoglobin level of ESA therapy was not 
specified.44-46 CMS’s requirements on the appropriate hemoglobin level of ESA treatment 
were more rigid than recommendations in the FDA labelling or ASCO/ASH guidelines. 
As specified in Medicare reimbursement policy change, ESA treatment was reasonable 
only when the hemoglobin level was < 10 g/dL.53 Different requirements on the 
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appropriate hemoglobin level of ESA treatment between Medicare reimbursement policy 
and the FDA labeling or ASCO/ASH guidelines might explain why the implementation 
of Medicare reimbursement policy did not have an impact on the risks of cardiovascular 
and thrombovascular events in incident users of ESAs with chemotherapy-induced 
anemia. 
Second, older adults are underrepresented or not included in some clinical trials 
examining the risks associated with ESAs. Current knowledge on the association between 
the hemoglobin level and the risks of cardiovascular and thrombovascular events in 
incident users of ESAs with chemotherapy-induced anemia are based on findings from 
clinical trials. Even though older adults are often included in some clinical trials, sample 
sizes of these clinical trials are usually not large enough for the subgroup analysis on the 
risks associated with ESAs in different age groups.92,93 The risks of cardiovascular and 
thrombovascular events associated with ESAs might be different between older adults 
and young or middle aged adults. If that is true, the association between the hemoglobin 
level and the risks of cardiovascular and thrombovascular events in incident users of 
ESAs with chemotherapy-induced anemia based on clinical trials of the adult population 
might not be the same in the older adult population. In addition, individuals who are 75 
years or older are not included in most clinical trials.94 The association between the 
hemoglobin level and the risks of cardiovascular and thrombovascular events in incident 
users of ESAs with chemotherapy-induced anemia identified in these clinical trials might 
not be generalizable to those who are 75 years or older. In this study, about half of the 
study population were 75 years or older. We had little knowledge on the association 
between the hemoglobin level and the risks of cardiovascular and thrombovascular events 
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in this population. The demographics of the study population in this study might explain 
why the implementation of Medicare reimbursement policy did not have an impact on the 
risks of cardiovascular and thrombovascular events in incident users of ESAs with 
chemotherapy-induced anemia. 
 
7.3 Discussion on the Costs 
 Results on the impact of Medicare reimbursement policy change on anemia-
related and total medical costs associated with ESAs in cancer patients with 
chemotherapy-induced anemia found in the study were similar to what we hypothesized. 
We hypothesized that in incident users of ESAs with chemotherapy-induced anemia, 
anemia-related and total medical costs were lower after Medicare reimbursement policy 
change compared to those before the policy change. The impact of the policy change on 
anemia-related costs (a 11.20% reduction) and total medical costs (a 11.96% reduction) 
in incident users of ESAs was similar. However, the impact of the policy change on 
different components of medical costs was different. In anemia-related costs, a greater 
cost saving was observed in patient cost-sharing (a 18.40% reduction) than Medicare 
payment (a 9.83% reduction). In total medical costs, cost savings in patient cost-sharing 
(a 13.58% reduction) and Medicare payment (a 11.59% reduction) were similar. 
 Medicare reimbursement policy change was effective in reducing medical costs 
associated with ESAs in cancer patients with chemotherapy-induced anemia from CMS’s 
perspective. How the policy change could impact the expenses by patient, third-party 
payers, and the whole society was not examined in this study. Medicare beneficiaries 
could sign an ABN for ESA services not reimbursed under CMS and be liable of paying 
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100% of the treatment expenses.54 When Medicare beneficiaries have supplemental 
insurances, they could seek reimbursement of ESA services from other insurers. If that is 
true, expenses from third-party payers might increase. When Medicare beneficiaries do 
not have any supplemental insurances, they need to pay ESA services out-of-pocket. If 
that is true, expenses from patient might increase. From the societal perspective, 
additional information is needed to understand the impact of Medicare reimbursement 
policy change on medical costs associated with ESAs in cancer patients with 
chemotherapy-induced anemia. 
 This study examined medical costs in incident users of ESAs with chemotherapy-
induced anemia during the one-year follow-up period. The impact of the policy change 
on medical costs in the long-term (more than one year) was not examined in this study. 
Some medical costs associated with ESAs (e.g. costs used to treat long-term adverse 
events) might occur one year after the index date. If that is true, we might be not able to 
observe all medical costs associated with ESAs during the one-year follow-up period. 
With a longer follow-up period, we might be able to have a complete picture of all 
medical costs associated with ESAs and thus better understand the long-term impact of 




This study has the following three policy significance. First, through examining 
the utilization of ESAs and blood transfusions before and after the implementation of 
Medicare reimbursement policy, it could help CMS understand both the short-term and 
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long-term effects of the policy change. Based on the current evidence in the literature, the 
effect of the policy change on the utilization of ESAs and blood transfusions during the 
complete pre- and post-policy periods was unknown. An understanding of the short-term 
and long-term effects of Medicare reimbursement policy on the intended change in ESAs 
and the possible unintended change in blood transfusions could help decision makers at 
CMS make appropriate policy decisions in the future to better meet the goal of CMS 
while considering both the intended and possible unintended policy consequence. Aim 1 
of the study was the first to examine the change in the utilization of ESAs (intended 
consequence) and blood transfusions (unintended consequence) after the implementation 
of Medicare reimbursement policy including the complete pre- and post-policy periods. 
Second, this study could help CMS understand whether the goal of Medicare 
reimbursement policy change, reducing potential harms caused by unreasonable or 
unnecessary ESA use, has been reached. In the U.S., the safety of ESAs is a significant 
concern for patients, healthcare providers, payers, and society. Understanding how the 
risks associated with ESAs changed after the implementation of Medicare reimbursement 
policy is critical for CMS to assess if the goal of the policy change has been achieved. 
Based on the current evidence in the literature, among users of ESAs, how risks would 
change after the implementation of Medicare reimbursement policy was unknown. Aim 2 
of the study enabled us to evaluate, for the first time, if Medicare reimbursement policy 
change reached its intended goal of reducing potential risks of cardiovascular and 
thrombovascular events associated with ESAs. 
Third, this study could help CMS understand the economic consequence of 
Medicare reimbursement policy change by examining the difference in medical costs 
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before and after the policy change. This information is of great significance to CMS 
because “smarter spending: lowering the total cost of care due to reduced monthly 
expenditures for Medicare beneficiary by improving care” is one of CMS’s top 
missions.95 As the highest-expenditure drug in the Medicare system before the policy 
change, medical costs associated with ESAs accounted for a significant proportion of 
CMS budget. CMS should find “new ways to pay for and deliver care that can lower 
costs and improve care”.95 By restricting unsafe use of ESAs, medical costs associated 
with ESAs would decrease. The issue, however, is that some other medical costs (e.g. 
costs of blood transfusions) might increase. Based on the current evidence in the 
literature, among users of ESAs, how anemia-related and total medical costs would 
change after the implementation of Medicare reimbursement policy was unknown. 
Therefore, it is critically important for CMS to understand both the intended and potential 
unintended economic consequence of the policy change when making policy decisions. 
Aim 3 of the study was the first to evaluate the economic consequence of Medicare 
reimbursement policy change among users of ESAs. 
In summary, the findings of this study are of great significance not only for 
evaluating the impact of Medicare reimbursement policy change, but also for providing 
critical empirical evidence for CMS’s future policy considerations. 
 
7.5 Innovation 
This study is innovative in the following five areas. First, this study was the first 
to assess the impact of Medicare reimbursement policy change on the risks and costs 
associated with ESAs. No previous studies have examined these issues in the literature. 
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Currently, the empirical evidence on the differences in the risks and costs associated with 
ESAs between the pre- and post-policy periods was not available. CMS, however, needs 
policy evaluation studies to assess if the goal of Medicare reimbursement policy change 
for ESAs in cancer patients has been achieved; and if the policy change generated cost 
savings among users of ESAs with chemotherapy-induced anemia. 
Second, this study was the first to incorporate a control group when assessing the 
impact of Medicare reimbursement policy change on the utilization of ESAs and blood 
transfusions. Previous studies examined the change in the utilization of ESAs and blood 
transfusions after the implementation of the policy only in cancer patients.73-78 Using the 
single group design in these published studies, however, was subject to threats to internal 
validity (e.g. history). Incorporating a control group in the design could eliminate 
multiple possible threats to internal validity, thus enhancing internal validity of the study. 
We also incorporated a control group when assessing the impact of Medicare 
reimbursement policy change on the costs associated with ESAs in cancer patients with 
chemotherapy-induced anemia. 
Third, better design and advanced statistical methodologies were used in the study 
to control for potential biases. (1) This study used an interrupted time series design to 
examine the changes in the utilization of ESAs and blood transfusions after the 
implementation of Medicare reimbursement policy.87 The interrupted time series design 
is a particularly strong quasi-experimental design with a high degree of internal validity 
when evaluating the impact of the policy change. This study design will allow us to 
control for confounding omitted variables and autocorrelation. (2) This study employed 
an incident user design to examine the risks and costs associated with ESAs, which 
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further enhanced the interval validity of the study.84 When events vary with time, the 
traditional prevalent user design could introduce bias because some early events are not 
measured. The incident user design, which is similar to clinical trials, could avoid this 
bias because all users have their own starting index dates and all the subsequent events 
during the follow-up period could be observed. Prior treatment could affect risk factors of 
future events. By using the incident user design, potential confounding variables were all 
measured at the beginning of each follow-up. (3) A difference-in-difference design was 
used in the study to examine the impact of Medicare reimbursement policy change on 
medical costs associated with ESAs.88 The underlying assumption of using a simple pre-
post design is that there is nothing associated with the outcome and that happened at the 
same time as the policy change. The difference-in-difference design does not require such 
an assumption because it has a comparison group which is not subject to the policy 
change. 
Fourth, this study examined the changes in the utilization of ESAs and blood 
transfusions including the complete pre- and post-policy periods. Previous studies have 
only examined the change before and after the implementation of Medicare 
reimbursement policy and found that after the policy change, the utilization of ESAs 
decreased by 26% to 57% and the utilization of blood transfusions remained constant or 
increased slightly.73-78 However, the latest information available in the literature 
regarding the utilization of ESAs and blood transfusions during the post-policy period 
was 2008.74 This study provided complete information on the utilization of ESAs and 
blood transfusions during the post-policy period until December 2009, before ESA 
REMS was implemented. 
 
114 
Fifth, this study used a large population-based dataset. Most of previous studies of 
Medicare reimbursement policy change reviewed medical records in local settings 
only.73,74,77,78 Many of these studies usually had small sample sizes and were not powered 
to detect the difference between the pre- and post-policy periods. In addition, their 
findings would likely not be generalizable to the U.S. population. Given that some risks 
associated with ESAs are not common, only population-based database, such as the 
SEER-Medicare database (a nationally representative database), would enable us to 
identify rare events. 
 
7.6 Limitation 
Three possible limitations of the study should be considered. First, an ideal 
control group should be similar to the treatment group in all aspects but not subject to 
Medicare reimbursement policy change. Specifically, the ideal control group for the 
study should be Medicare beneficiaries with cancer who used ESAs to treat 
chemotherapy-induced anemia but not subject to the policy change. However, finding a 
perfect control could be challenging. Our control group consisted CKD patients who used 
ESAs when they had low levels of hemoglobin. The advantage of this control group is 
that it is not subject to the policy change; while, the limitation is that this control group 
may not be similar to the treatment group in all aspects. 
Second, some potential confounding variables were not observed in the study. In 
the conceptual framework, we identified some internal factors that could influence the 
association between the policy change and health outcomes. However, some of them, 
which were potential confounding variables, were not controlled for in the study. The 
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SEER-Medicare database contain little information on physician characteristics (e.g. 
employment setting and previous experience), behavioral factors (e.g. smoking and 
alcohol use), and patient risk factors (e.g. obesity and family history of cancer), thus 
limiting our ability to measure and control for these potential confounding variables in 
the study. However, this study incorporated a control group in the study design, which 
enabled us to control for biases caused by confounding variables common to the 
treatment and control groups, even when they were unobserved. 
Third, the utilization of ESAs under Medicare Part D was not measured in the 
study. ESAs are covered under Medicare Part B when administered in physician’s offices 
and are covered under Medicare Part D when administered outside physician’s offices. 
Because Medicare Part D claims were first available in the SEER-Medicare database in 
2007, the pre-policy period did not have ESA treatment information under Medicare Part 
D. For a fair comparison between the pre- and post-policy periods, we chose to not 
measure the utilization of ESAs under Medicare Part D in this study. However, the 
impact of missing Medicare Part D information on the validity and accuracy of study 
results should be minimum because this study included a control group and ESA use 
under Medicare Part D only accounted for a small proportion of all ESA use.96 
In summary, because we have incorporated a control group in the study design, 
the impact of limitations on the internal validity of study results should be minimal.  
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  CHAPTER 8
CONCLUSION 
 
This study found that Medicare reimbursement policy change had an impact on 
the utilization of ESAs and blood transfusions in cancer patients with chemotherapy-
induced anemia. Medicare reimbursement policy had a one-time only effect on the 
utilization of ESAs. After the policy change, the monthly utilization of ESAs had a 
relative 50% reduction. Medicare reimbursement policy also had a one-time only effect 
on the utilization of blood transfusions. After the policy change, the monthly utilization 
of blood transfusions had a relative 10% increase. The goal of Medicare reimbursement 
policy change was to reduce potential harms caused by unreasonable or unnecessary ESA 
use. So, the impact of the policy change on the utilization of ESAs was intended but the 
impact on the utilization of blood transfusions was indirect and unintended. For CMS’s 
future policy considerations, in addition to predict and study the intended changes caused 
by the policy, the possible unintended changes should also be studied. 
This study found that Medicare reimbursement policy change had no impact on 
the risks associated with ESAs in cancer patients with chemotherapy-induced anemia. 
The risks of MI, stroke, and VTE associated with ESAs during the one-year follow-up 
period in cancer patients with chemotherapy-induced anemia was not changed after the 
implementation of Medicare reimbursement policy. Further studies are needed to 
understand why Medicare reimbursement policy change did not reach its goal of reducing 
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potential risks associated with ESAs. CMS should reevaluate the appropriateness of 
Medicare reimbursement policy change and make necessary changes on the current 
regulations if future studies confirm our findings. 
This study found that Medicare reimbursement policy change had an impact on 
the costs associated with ESAs in cancer patients with chemotherapy-induced anemia. 
Anemia-related and total medical costs associated with ESAs during the one-year follow-
up period in cancer patients with chemotherapy-induced anemia were reduced by about 
10% after the implementation of Medicare reimbursement policy. This study provided 
evidence on the economic consequence of the policy change in cancer patients with 
chemotherapy-induced anemia. ESAs were the highest-expenditure drug in the Medicare 
system before the implementation of Medicare reimbursement policy. This policy change 
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